<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">107785</article-id>
<article-id pub-id-type="doi">10.7554/eLife.107785</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107785.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.3</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Structural Biology and Molecular Biophysics</subject>
</subj-group>
</article-categories><title-group>
<article-title><italic>In silico</italic> design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yang</surname>
<given-names>Yanqing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
    <xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Qiao</surname>
<given-names>Lulu</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
    <xref ref-type="author-notes" rid="n1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yangwei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Zhiye</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<email>wangzhiye1@zju.edu.cn</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7297-5083</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>zhangd_iqb@zju.edu.cn</email>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9924-128X</contrib-id>
<name>
<surname>Buratto</surname>
<given-names>Damiano</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3400-0685</contrib-id>
<name>
<surname>Huang</surname>
<given-names>Liquan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8624-5591</contrib-id>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<email>rhzhou@zju.edu.cn</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>Institute of Quantitative Biology, College of Life Sciences, Zhejiang University</institution></institution-wrap>, <city>Hangzhou</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>State Key Laboratory of Plant Environmental Resilience, College of Life Sciences, Zhejiang University</institution></institution-wrap>, <city>Hangzhou</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>The First Affiliated Hospital, College of Medicine, Zhejiang University</institution></institution-wrap>, <city>Hangzhou</city>, <country country="CN">China</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Frank</surname>
<given-names>Aaron</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/049d04r12</institution-id><institution>Arrakis Therapeutics</institution>
</institution-wrap>
<city>Waltham</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Cui</surname>
<given-names>Qiang</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/05qwgg493</institution-id><institution>Boston University</institution>
</institution-wrap>
<city>Boston</city>
<country country="US">United States</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
    <fn id="n1" fn-type="equal"><label>*</label><p>These authors contributed equally</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: No competing interests declared</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2025-09-10">
<day>10</day>
<month>09</month>
<year>2025</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2026-01-29">
<day>29</day>
<month>01</month>
<year>2026</year>
</pub-date>
<volume>14</volume>
<elocation-id>RP107785</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2025-06-04">
<day>04</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2025-06-08">
<day>08</day>
<month>06</month>
<year>2025</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.06.04.657802"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2025-09-10">
<day>10</day>
<month>09</month>
<year>2025</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107785.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.107785.1.sa3">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107785.1.sa2">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.107785.1.sa1">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.107785.1.sa0">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2025, Yang et al</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Yang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-107785-v2.pdf"/>
<abstract><p>Nucleic acid aptamers hold promise for clinical applications, yet understanding their molecular binding mechanisms to target proteins and efficiently optimizing their binding affinities remain challenging. Here, we present CAAMO (<underline>C</underline>omputer-<underline>A</underline>ided <underline>A</underline>ptamer <underline>M</underline>odeling and <underline>O</underline>ptimization), which integrates <italic>in silico</italic> aptamer design with experimental validation to accelerate the development of aptamer-based RNA therapeutics. Starting from the sequence information of a reported RNA aptamer, Ta, for the SARS-CoV-2 spike protein, our CAAMO method first determines its binding mode with the spike protein’s receptor binding domain (RBD) through a multi-strategy computational approach. We then optimize its binding affinity <italic>via</italic> structure-based rational design. Among the six designed candidates, five were experimentally verified and exhibited enhanced binding affinities compared to the original Ta sequence. Furthermore, we directly compared the binding properties of the RNA aptamers to neutralizing antibodies, and found that the designed aptamer Ta<sup>G34C</sup> demonstrated a comparable binding affinity to the RBD compared to all tested neutralizing antibodies. This highlights its potential as an alternative to existing COVID-19 antibodies. Our work provides a robust approach for the efficient design of a relatively large number of high-affinity aptamers with complicated topologies. This approach paves the way for the development of aptamer-based RNA diagnostics and therapeutics.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>RNA aptamer</kwd>
<kwd>rational design</kwd>
<kwd>molecular dynamics</kwd>
<kwd>electrophoretic mobility shift assay</kwd>
<kwd>SARS-CoV-2</kwd>
</kwd-group>
<funding-group>
<award-group id="par-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/027s68j25</institution-id>
<institution>MOST | National Key Research and Development Program of China (NKPs)</institution>
</institution-wrap>
</funding-source>
<award-id>2021YFF1200404</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-2">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/027s68j25</institution-id>
<institution>MOST | National Key Research and Development Program of China (NKPs)</institution>
</institution-wrap>
</funding-source>
<award-id>2024YFA1307502</award-id>
<principal-award-recipient>
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-3">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>MOST | National Natural Science Foundation of China (NSFC)</institution>
</institution-wrap>
</funding-source>
<award-id>12474203</award-id>
<principal-award-recipient>
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-4">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01h0zpd94</institution-id>
<institution>MOST | National Natural Science Foundation of China (NSFC)</institution>
</institution-wrap>
</funding-source>
<award-id>U1967217</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-5">
<funding-source>
<institution-wrap>
<institution>Zhejiang Provincial Natural Science Foundation of China</institution>
</institution-wrap>
</funding-source>
<award-id>LZ25A040001</award-id>
<principal-award-recipient>
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-6">
<funding-source>
<institution-wrap>
<institution>National Independent Innovation Demonstration Zone Shanghai Zhangjiang Major Projects</institution>
</institution-wrap>
</funding-source>
<award-id>ZJZX2020014</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-7">
<funding-source>
<institution-wrap>
<institution>Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University</institution>
</institution-wrap>
</funding-source>
<award-id>SN-ZJU-SIAS-003</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-8">
<funding-source>
<institution-wrap>
<institution>Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University</institution>
</institution-wrap>
</funding-source>
<award-id>SN-ZJU-SIAS-006</award-id>
<principal-award-recipient>
<name>
<surname>Huang</surname>
<given-names>Liquan</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-9">
<funding-source>
<institution-wrap>
<institution>Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University</institution>
</institution-wrap>
</funding-source>
<award-id>SN-ZJU-SIAS-009</award-id>
<principal-award-recipient>
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-10">
<funding-source>
<institution-wrap>
<institution>National Center of Technology Innovation for Biopharmaceuticals</institution>
</institution-wrap>
</funding-source>
<award-id>NCTIB2022HS02010</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-11">
<funding-source>
<institution-wrap>
<institution>Shanghai Artificial Intelligence Lab</institution>
</institution-wrap>
</funding-source>
<award-id>P22KN00272</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="par-12">
<funding-source>
<institution-wrap>
<institution>Zhejiang University Global Partnership Fund</institution>
</institution-wrap>
</funding-source>
<award-id>188170+194452409/004</award-id>
<principal-award-recipient>
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>1.We explicitly clarified that the lead aptamer Ta was previously identified through multi-round SELEX with negative selection and validated by SPR/BLI as a high-affinity, high-specificity RBD binder, providing a solid starting point for optimization.
2.We extended free energy perturbation (FEP/HREX) analyses to multiple SARS-CoV-2 variants, demonstrating that the optimized aptamer TaG34C retains enhanced and broad-spectrum affinity across Alpha, Beta, and Omicron sublineages.
</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<label>1.</label><title>Introduction</title>
<p>Aptamers are short, single-stranded RNA or DNA oligonucleotides that bind tightly and specifically to target molecules [<xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref>], earning the designation of “chemical antibodies” [<xref ref-type="bibr" rid="c3">3</xref>,<xref ref-type="bibr" rid="c4">4</xref>]. They combine the advantageous properties of small organic compounds and antibodies, exhibiting strong affinity and specificity comparable to monoclonal antibodies, while remaining mostly non-immunogenic and highly capable of tissue penetration similar to those of small molecules [<xref ref-type="bibr" rid="c5">5</xref>]. These versatile attributes have led to their widespread applications in biomedical fields, including drug discoveries [<xref ref-type="bibr" rid="c6">6</xref>], biomarker identifications [<xref ref-type="bibr" rid="c7">7</xref>], therapeutics [<xref ref-type="bibr" rid="c8">8</xref>], diagnostics [<xref ref-type="bibr" rid="c9">9</xref>], and biosensors [<xref ref-type="bibr" rid="c10">10</xref>]. The U.S. Food and Drug Administration’s (FDA) approval of Macugen (pegaptanib sodium, Pfizer / Eyetech) in 2004, which targets vascular endothelial growth factor (VEGF) to treat wet age-related macular degeneration, was a landmark achievement for aptamer-based drugs [<xref ref-type="bibr" rid="c11">11</xref>]. This success has driven further exploration of aptamer-based therapies. To date, a variety of aptamers have been proposed to neutralize a range of disease-related proteins, such as human epidermal growth factor receptor 2 (HER2) [<xref ref-type="bibr" rid="c12">12</xref>], epidermal growth factor receptor (EGFR) [<xref ref-type="bibr" rid="c13">13</xref>], and prostate-specific membrane antigen (PSMA) [<xref ref-type="bibr" rid="c14">14</xref>]. Recently, the significant contributions of mRNA vaccines [<xref ref-type="bibr" rid="c15">15</xref>], aptamers [<xref ref-type="bibr" rid="c16">16</xref>] and other RNA biotherapeutics [<xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c18">18</xref>] have highlighted the potential of RNA-based interventions during the COVID-19 pandemic. This global health crisis has underscored the importance of RNA therapeutics, including medical aptamers.</p>
<p>The systematic evolution of ligands by exponential enrichment (SELEX) technique, the most commonly used method for aptamer screening, still faces several challenges [<xref ref-type="bibr" rid="c19">19</xref>]. Firstly, due to its random selection, the candidate aptamers are identified regardless of any atomic mechanisms underlying the interactions between the nucleic acids and target proteins; and secondly, because of limited sizes of oligonucleotide libraries, the identified candidates may not be the best aptamers, which, instead, can be used as lead sequences for further optimization [<xref ref-type="bibr" rid="c20">20</xref>]. Therefore, developing <italic>in silico</italic> methods that can complement SELEX screening and provide atomic structure-based rational aptamer design is highly desirable. For instance, we successfully developed two optimized RNA aptamers targeting epithelial cellular adhesion molecule (EpCAM) using a structure-based <italic>in silico</italic> method. We further confirmed their enhanced affinities compare to a previously patented nanomolar aptamer [<xref ref-type="bibr" rid="c21">21</xref>].</p>
<p>These two EpCAM-targeted aptamers were relatively small (19 nucleotides) and structurally simple, with a 4-bp stem and a 10-nucleotide long hairpin loop. Their simplicity allowed for precise determination of the aptamer-protein complex structure and enabled structure-based design through conventional computational modelling and simulations. In comparison, RNA aptamers screened through SELEX technique are typically much larger, often comprising tens of nucleotides and featuring complex topologies, including tertiary structural motifs such as internal loops and G-quadruplex. These features not only contribute to increased difficulties in accurate structure modelling, but also increase the possibilities of conformational changes upon binding to the target molecules (i.e. folding upon binding) [<xref ref-type="bibr" rid="c22">22</xref>]. Furthermore, the limited number of experimentally determined structures for aptamer-protein complexes in the Protein Data Bank (PDB) present further challenges for an accurate structure modelling. These limitations highlight the need for more advanced computational frameworks to accurately predict the binding modes of RNA aptamers of varying sizes and topologies, thus enabling efficient <italic>in silico</italic> aptamer engineering.</p>
<p>A direct comparison between aptamers (also known as “chemical antibodies”) and conventional biological antibodies in terms of binding mechanisms and affinities is of great interest. However, such comparative studies are currently limited. A prerequisite for such comparison is the availability of a target protein of functional importance for which both effective aptamers and antibodies exist. The receptor binding domain (RBD) of the spike (S) protein expressed by the SARS-CoV-2 is one such target (see <xref rid="fig1" ref-type="fig">Fig. 1A</xref>). It binds to human angiotensin-converting enzyme 2 (ACE2) with high affinity to facilitate viral entry into host cells [<xref ref-type="bibr" rid="c23">23</xref>,<xref ref-type="bibr" rid="c24">24</xref>]. Targeting RBD to block the interactions between SARS-CoV-2 spike protein and human ACE2 emerged as a promising therapeutic strategy [<xref ref-type="bibr" rid="c25">25</xref>] to fight COVID-19 pandemic. For example, RBD-targeted antibodies have shown substantial therapeutic potential due to their potent neutralizing effects [<xref ref-type="bibr" rid="c26">26</xref>,<xref ref-type="bibr" rid="c27">27</xref>]. Alternatively, a recent study reported an RNA aptamer generated through SELEX, termed RBD-PB6-Ta (hereafter referred to as “Ta”), that binds to the RBD of SARS-CoV-2 spike protein with high affinity and efficiently blocks viral infection at low concentrations (see <xref rid="fig1" ref-type="fig">Fig. 1B</xref>) [<xref ref-type="bibr" rid="c16">16</xref>]. This aptamer was originally identified through SELEX and subsequently validated using surface plasmon resonance (SPR) and biolayer interferometry (BLI), which confirmed its high affinity (sub-nanomolar) and high specificity toward the RBD. Therefore, Ta provides a well-characterized and biologically relevant starting point for structure-based optimization. Based on these observations, the RBD of SARS-CoV-2 spike protein represents an ideal target to directly compare the efficacy of aptamers and antibodies. Such comparisons could enhance our understanding of the aptamer binding mechanism, guiding the rational design of aptamers that can possibly be comparable with or even superior to neutralizing antibodies, thereby complementing the existing means of treatment (see <xref rid="fig1" ref-type="fig">Fig. 1C</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1.</label>
    <caption><title>The workflow of the CAAMO framework for designing high-affinity RNA aptamers and its application in the development of novel RNA aptamers targeting the RBD of the SARS-CoV-2 spike protein.</title>
        <p>(A) Schematic diagram of the spike protein (trimer) of SARS-CoV-2 virus with one of the three RBD regions highlighted in gold. (B) The sequence and Mfold-predicted secondary structure of a SELEX-derived RNA aptamer termed Ta targeting the RBD of SARS-CoV-2 spike protein, which was the initial input information of the CAAMO framework. (C) Schematic diagrams showing that high-affinity RNA aptamers optimized through the CAAMO framework can complement existing antibody-neutralizing treatments for COVID-19. Antibodies (purple) and RNA aptamers (yellow) that bind to the RBDs of the SARS-CoV-2 spike protein can neutralize viral infection by blocking its interaction with the human ACE2. The designed aptamers (marked by red dots) with binding affinities comparable to antibodies can further strengthen the neutralizing treatment when antibody escape occurs. (D) Illustrative workflow of the CAAMO framework by integrating computational techniques with experimental validation. (E) A representative output after CAAMO framework optimization (the aptamer Ta<sup>G34C</sup>) and its comparison with the original Ta sequence. RNA aptamer is colored by pink and RBD is shown in dark blue surface. The mutated nucleotides (G34 in wild type Ta and C34 in optimized Ta<sup>G34C</sup>) are highlighted in pink sticks, atoms oxygen and nitrogen are colored by red and blue, respectively. (F) Competitive binding experiments to compare the binding capabilities of RNA aptamers Ta or Ta<sup>G34C</sup> and a commercial neutralizing antibody (SinoBiological, Cat: 40592-R001) to the RBD of SARS-CoV-2 spike protein. Gradient amount of the commercial neutralizing antibody was titrated into the buffer containing 5 μM aptamer (Ta or Ta<sup>G34C</sup>) and 40 μM RBD. The intensity of aptamer-RBD bands were quantified with Image J and normalized to that of the mixture without antibody, which was set to 100%. Data were collected from the images of EMSA shown in <xref ref-type="fig" rid="fig5">Fig. 5D</xref>.</p></caption>
<graphic xlink:href="657802v3_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In this work, we present the CAAMO (<underline>C</underline>omputer-<underline>A</underline>ided <underline>A</underline>ptamer <underline>M</underline>odeling and <underline>O</underline>ptimization) framework, which combines computational techniques and experimental validation to design high-affinity aptamers. Rather than serving as a de novo aptamer discovery tool, CAAMO is designed as a post-SELEX optimization platform that rationally improves the binding capability of existing aptamers. Starting with an RNA sequence, we first predicted the most probable binding mode of the RNA aptamer with the target protein using a combination of <italic>in silico</italic> methods, including RNA structure prediction, ensemble docking, molecular dynamics (MD) simulations, steered molecular dynamics (SMD) simulations, and binding free energy calculations. We then performed a comparative analysis between the aptamer Ta and several popular neutralizing antibodies, focusing on their binding sites (using computational methods) and binding capabilities (through both computational and experimental approaches). We identified potential mutation sites for affinity enhancement and developed six novel aptamers through <italic>in silico</italic> mutagenesis study with free energy perturbation (FEP) method. Among these, electrophoretic mobility shift assay (EMSA) experiments confirmed that five had improved binding affinities compared to the original aptamer Ta. Notably, the aptamer Ta<sup>G34C</sup> exhibited the highest binding affinity to the RBD, outperforming all tested neutralizing antibodies in competitive binding assays. These findings demonstrate the effectiveness of the CAAMO framework in developing high-affinity RNA aptamers targeting the RBD of SARS-CoV-2 spike protein, providing new therapeutic strategies against COVID-19. Moreover, the CAAMO framework can be extended to aptamers that are larger and with more complex topologies.</p>
</sec>
<sec id="s2">
<label>2.</label><title>Results</title>
<sec id="s2a">
<label>2.1</label><title>Overview of the CAAMO framework for high-affinity RNA aptamer design</title>
<p>For RNA aptamers composed of tens of nucleotides with complicated topological structures, accurately determining their binding modes with target proteins is challenging due to the huge conformational space available, which hinders efforts in structure-based design of high-affinity aptamers. To address these challenges, we propose a promising framework named CAAMO, which integrates computational techniques with experimental validation. This CAAMO framework is designed not only to provide the structural insights into key nucleic acid-protein interactions but also to facilitate the efficient design of aptamers with enhanced affinity. The framework consists of four main phases (see <xref rid="fig1" ref-type="fig">Fig. 1D</xref> and Fig. S1): (i) constructing an aptamer conformational ensemble by employing several cutting-edge RNA three-dimensional (3D) structure prediction methods, (ii) identifying an appropriate aptamer binding mode through integrating conformational selection docking, induced-fit dynamic simulation [<xref ref-type="bibr" rid="c28">28</xref>], and binding energy-guided filtration, (iii) optimizing the aptamer sequence through <italic>in silico</italic> mutagenesis study using free energy perturbation calculations, and (iv) final experimental validation of the designed aptamer candidates. Further details on the CAAMO framework are provided in the following subsections and in the “Materials and Methods” section.</p>
<p>An RNA aptamer sequence termed “Ta” (containing 52 nucleotides; see <xref rid="fig1" ref-type="fig">Fig. 1B</xref>), previously shown to bind the RBD of SARS-CoV-2 spike protein with high affinity [<xref ref-type="bibr" rid="c16">16</xref>], was chosen to illustrate the CAAMO framework. The initial input to the CAAMO is the nucleotide sequence of the aptamer Ta, and the output is several <italic>computationally</italic> designed and subsequently <italic>experimentally</italic> validated aptamers with improved binding affinities compared to the initial sequence. A representative output (the aptamer Ta<sup>G34C</sup>), that exhibits a ∼3.3-fold stronger binding affinity than the original aptamer Ta, is shown in <xref rid="fig1" ref-type="fig">Fig. 1E</xref>. Notably, the success rate of the <italic>in silico</italic> design via the CAAMO framework is very promising, with five out of the six (∼83%) computationally designed candidate aptamers experimentally confirmed to have improved binding affinities. Furthermore, competitive binding experiments with popular neutralizing antibodies revealed that the designed RNA aptamer Ta<sup>G34C</sup> has a higher binding affinity to the RBD of SARS-CoV-2 spike protein than the neutralizing antibodies (see <xref rid="fig1" ref-type="fig">Fig. 1F</xref>). Thus, the newly identified aptamer Ta<sup>G34C</sup> shows great potential as a complement to existing antibody-based neutralizing treatments for COVID-19, especially when antibody escape occurs in emerging SARS-CoV-2 variants [<xref ref-type="bibr" rid="c29">29</xref>]. Overall, these results not only indicate the proposed putative binding conformation of the aptamer Ta to the RBD as a reasonable representation of the binding complex, but also demonstrate the great potential of our CAAMO framework in aptamer design and optimization.</p>
</sec>
<sec id="s2b">
<label>2.2</label><title>Determination of the binding model of the aptamer Ta to the RBD</title>
<p>Accurately predicting the binding complex of the RNA aptamer with the target protein is a critical step in structure-based <italic>in silico</italic> aptamer design, especially with aptamers of multiple nucleotides and complex topologies. To address this challenge, we constructed a multi-strategy approach that includes RNA 3D structure prediction, ensemble docking/clustering, and binding capacity assessment to identify the most probable binding conformation of the aptamer Ta with the RBD of SARS-CoV-2 spike protein (see <xref rid="fig2" ref-type="fig">Fig. 2A</xref>). The RBD conformation was extracted from the crystal structure of the RBD-ACE2 complex (PDB id: 6LZG) and then refined using MD simulation (see Fig. S2). For the aptamer Ta, we first predicted its secondary structure using Mfold [<xref ref-type="bibr" rid="c30">30</xref>], forming a stem-loop structure containing five stems, two internal loops, two bulges and one hairpin loop (see <xref rid="fig1" ref-type="fig">Fig. 1B</xref>). Then, we built a 3D conformational ensemble using the state-of-the-art RNA 3D structure prediction models because of the inherent flexibility of unpaired nucleotides in loop regions and potential conformational changes upon binding to the target protein. A total of 25 representative aptamer Ta structures with different degrees of bending (see Fig. S3A) were selected for subsequent molecular docking. It should be noted that, since most popular structure prediction models, such as FARFAR2 [<xref ref-type="bibr" rid="c31">31</xref>], IsRNA2 [<xref ref-type="bibr" rid="c32">32</xref>] and SimRNA [<xref ref-type="bibr" rid="c33">33</xref>], adopt a conformation clustering strategy to obtain the top predictions, each of these 25 predicted structures represents a collection of similar 3D conformations.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 2.</label>
    <caption><title>Determination of the binding model of the aptamer Ta and the RBD of the SARS-CoV-2 spike protein <italic>via</italic> a multi-strategy approach.</title>
        <p>(A) Flowchart illustrating the combination of RNA 3D structure prediction, ensemble docking and clustering, and binding capacity assessment by MM/GBSA and steered MD to determine the most probable binding conformation of the aptamer Ta to the RBD. (B) Six main binding modes, i.e., conformations 01-06, with clearly distinct binding conformations after ensemble docking and clustering for further binding ability assessment. The RBD and the aptamer Ta are shown in dark blue and dark red, respectively. For clarity, the surface of RBD is also displayed. For the aptamer Ta, conformations 01-06 are named in a descending order of their respective cluster sizes and their colors are lightened gradually. (C) The binding energies between the aptamer Ta and RBD estimated by MM/GBSA method for six binding candidates shown in plane (B). Data represent mean±s.d. collected from three independent calculations. (D) The rupture works required to separate the bound aptamer Ta from the RBD for different binding conformation candidates. Data were collected from four independent steered MD simulations. Limited by the available computing resources, only the first four binding conformations were assessed. The orange line is the median, boxes extended form lower to upper quartiles, whiskers showing the range of nonoutlier data. (E) Overview of the most probable binding model (conformation 01) of the aptamer Ta and RBD. The RBD is shown in cyan cartoon representation, the apical loop, bulge part, and end stem of the aptamer Ta are colored plum, pink, and sandy brown, respectively. The key residues of the RBD and nucleotides of the aptamer Ta for binding interactions are shown in sticks, all nitrogen atoms colored by blue, and all oxygen atoms by red. (F) EMSA results of the aptamer Ta (upper panel) and the weakly binding aptamer Tc (negative control, lower panel) bound to the RBD of the SARS-CoV-2 spike protein and (G) the resultant binding curve for the aptamer Ta. The dissociation constant (<italic>K<sub>d</sub></italic>) was calculated from the EMSA image quantification from three independent experiments.</p></caption>
<graphic xlink:href="657802v3_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>From the ensemble docking complex pool (containing 1,000 aptamer-RBD binding poses; see Fig. S3B), we generated six major clusters, each representing distinct binding conformations. For each cluster, we selected the structure with the lowest binding energy, estimated using the molecular mechanics generalized Born surface area (MM/GBSA) approach based on single-frame conformation, as the representative binding conformation (see <xref rid="fig2" ref-type="fig">Fig. 2B</xref> and conformations 01-06 in Fig. S3C). MD simulations of these six representative conformations confirmed that they maintained stable binding modes over the course of the long-time simulations (see Fig. S4). We further analyzed the binding abilities between the aptamer Ta and RBD for these six MD refined conformations using MM/GBSA and steered molecular dynamics (SMD) simulations to determine the most likely binding conformation. As shown in <xref rid="fig2" ref-type="fig">Fig. 2C</xref>, the MM/GBSA binding energy of conformation 01 (Δ<italic>G</italic>=-142.93±7.65 kcal/mol) is significantly lower than the other five candidates (Δ<italic>G</italic>&gt;-120 kcal/mol). Interestingly, we found that the binding energy of each conformation correlated with the sizes of its corresponding clusters (see <xref rid="fig2" ref-type="fig">Fig. 2C</xref> and Fig. S3C), with a larger cluster associated with lower binding energy. Additionally, we computed the rupture works required to separate the bound aptamer from the RBD using SMD simulations. Among four tested cases (conformations 01-04), the conformation 01 rupture work is the largest (254.2±47.9 kcal/mol) and significantly different from that of the other conformations (see <xref rid="fig2" ref-type="fig">Fig. 2D</xref>). Despite the limitations of MM/GBSA and SMD methods (more rigorous FEP method will be used later), both approaches consistently showed that conformation 01 had the strongest binding ability between the aptamer Ta and the RBD. Based on these results, we selected conformation 01 as the putative binding model for further structure-based rational design of high-affinity aptamers.</p>
<p>In the putative binding complex, the aptamer Ta adopts a saddle-like shape to bind the RBD (see <xref rid="fig2" ref-type="fig">Fig. 2E</xref>). We divided the aptamer into three parts: the apical loop (contains two base pairs; nucleotides C24-C33), the bulge region (nucleotides G11-C23 and G34-C41), and the end stem part (contains one mismatch base pair; nucleotides G1-U10 and A42-A52). The apical loop and end stem parts bind to opposite sides of the RBD, respectively, while the bulge acts as a linker, adjusting the bending angle of the saddle-like shape. The binding between the aptamer Ta and RBD is stabilized by electrostatic, hydrogen bonding, and van der Waals interactions. In details, some important interactions include the electrostatic interactions between the phosphate groups of nucleotides C29 and U30 and the basic amino acid ARG408, and between the phosphate groups of C3, A42 and G43 and the LYS444; the hydrogen bonds between GLN409@Nε2-Hε21…C29@O2’, LYS417@Nζ-Hζ3…U31@O2, U42@O2’-HO2’…ASN448@Oδ1, ASN450@N-H…U42@ O2’, A14@N6-H61…GLY482@O, A14@O2’-HO2’…GLU484@Oε2, ASN487@ Nδ2-Hδ22…C24@O2’ and TYR489@OH-HH…G25@O2’ and the van der Waals packing interactions between nucleotides of the apical loop part and some aromatic residues of the RBD (such as TYR421, TYR453, PHE456, TYR473, PHE486, and PHE489) (see Fig. S5). These detailed interactions provide important insights for future <italic>in silico</italic> aptamer design.</p>
<p>In addition to the aptamer Ta, we also analyzed a weaker binding aptamer sequence, RBD-PB6-Tc (Tc), as a negative control [<xref ref-type="bibr" rid="c16">16</xref>]. We constructed a binding model for the Tc sequence with the RBD using the same approach as for the aptamer Ta (see Fig. S6). SMD simulations confirmed that the binding strength of Tc to the RBD was significantly weaker than that of the aptamer Ta (see Fig. S6D), which proves the reliability of our approach to determine the binding model of an RNA aptamer with a target protein. Additionally, our EMSA experiments also confirmed that the binding affinity of the Ta-RBD complex is stronger than that of the Tc-RBD complex (see <xref rid="fig2" ref-type="fig">Figs. 2F</xref> and <xref rid="fig2" ref-type="fig">2G</xref>), in good agreement with the previous study [<xref ref-type="bibr" rid="c16">16</xref>]. The measured dissociation constant for the Ta-RBD complex is <italic>K<sub>d</sub></italic>=110.7 μM, while the sequence Tc is unable to bind to the RBD under all conditions tested.</p>
<p>These results motivate the design of high-affinity RNA aptamers targeting the RBD of the SARS-CoV-2 spike protein to enhance the treatment of COVID-19.</p>
</sec>
<sec id="s2c">
<label>2.3</label><title>Comparison of binding properties between the aptamer Ta and neutralizing antibodies</title>
<p>In recent years, researchers have developed numerous antibodies to neutralize SARS-CoV-2 infection by blocking the RBD of the spike protein from binding to ACE2 [<xref ref-type="bibr" rid="c34">34</xref>]. Their binding properties with the RBD have been extensively studied. Since we determined the most probable binding model of the aptamer Ta to the RBD, comparing the binding properties of the aptamer Ta with those of the neutralizing antibodies to the RBD is both feasible and meaningful. A preliminary comparison of the respective binding modes of ACE2, the aptamer Ta, and neutralizing antibodies to the RBD (see Fig. S7A) indicates that the aptamer Ta can precisely occupy the binding site of ACE2, similar to many neutralizing antibodies, thereby blocking SARS-CoV-2 invasion. To further explore this, we analyzed the contact ratios of residues on the RBD bound to ACE2 (derived from MD simulations), to the aptamer Ta (derived from MD simulations), or to the neutralizing antibodies (from all available crystal structures deposited in PDB). And the results indicate that the contact regions on the RBD bound by the aptamer Ta, ACE2 or the neutralizing antibodies were largely similar (<xref rid="fig3" ref-type="fig">Fig. 3A</xref>). Additionally, we analyzed the electrostatic potential distribution on the RBD surface to assess how the highly negatively charged RNA aptamer interacts with the RBD (see <xref rid="fig3" ref-type="fig">Fig. 3A</xref>). The positively charged regions on both sides of the RBD promote the aptamer binding. To quantitatively analyze the binding complexes, we defined a key residue as the one with a contact ratio greater than 0.5. We found that ACE2 binds to the RBD using 12 key residues, such as LYS417, LEU455, PHE456, ALA475 (see <xref rid="fig3" ref-type="fig">Fig. 3B</xref>) while the neutralizing antibodies engage 19 key residues on the RBD, including all of ACE2’s key residues except for THR500. This higher number of key residues corresponds with the stronger binding ability of neutralizing antibodies compare to ACE2, enhancing their ability to block SARS-CoV-2 invasion. For the aptamer Ta, we identified 27 key residues, most of which overlap with those of ACE2 and neutralizing antibodies. For instance, nine key residues on the RBD are shared by ACE2, neutralizing antibodies, and the aptamer Ta (see <xref rid="fig3" ref-type="fig">Fig. 3B</xref>), suggesting that the aptamer Ta may have comparable or even better binding ability to the RBD compared to the neutralizing antibodies.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 3.</label>
    <caption><title>The aptamer Ta exhibits a comparable binding capability to RBD compared to neutralizing antibodies.</title>
        <p>(A) Contact ratios of residues on the RBD by ACE2 (derived from MD simulations), the aptamer Ta (derived from MD simulations), and neutralizing antibodies (derived from all available crystal structures deposited in PDB). For reference, the electrostatic potential distribution on the RBD surface generated by PyMOL (version 2.3.5) program was also shown. (B) Key residues on RBD (with contact ratio larger than 0.5 in plane (A)) contacted by ACE2, the aptamer Ta, and neutralizing antibodies were displayed as a Venn diagram. (C) Binding energies estimated by MM/GBSA calculations for ACE2, the aptamer Ta, and three representative antibodies (P2C-1F11, 2H2, and S2E12) binding to RBD. (D) Binding ability of a commercial antibody (40592-R001) to RBD was examined by a protein binding assay. Three micrograms of RBD protein and 3 μg of the antibody individually or mixed together were run a native-PAGE gel, which then was stained with Coomassie brilliant blue. (E) The RBD binding abilities of the aptamer Ta and commercial antibody 40592-R001 were compared by EMSA competitive binding experiments. The aptamer-RBD complex bands were shown after running on an agarose gel following the incubation of 40 μM RBD protein, 5 μM aptamer Ta and the antibody 40592-R001.</p></caption>
<graphic xlink:href="657802v3_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We performed binding energy estimations using MM/GBSA calculation and competitive binding assays with EMSA experiments to further compare the binding abilities of the aptamer Ta and neutralizing antibodies to the RBD. We selected three potent antibodies that can effectively neutralize SARS-CoV-2 infection, including antibody P2C-1F11 [<xref ref-type="bibr" rid="c35">35</xref>] (PDB id: 7CDI), 2H2 [<xref ref-type="bibr" rid="c36">36</xref>] (PDB id: 7DK4), and S2E12 [<xref ref-type="bibr" rid="c34">34</xref>] (PDB id: 7K4N), and calculated their binding energy to the RBD, along with that of ACE2. As shown in <xref rid="fig3" ref-type="fig">Fig. 3C</xref>, antibodies P2C-1F11 (−119.24±7.86 kcal/mol) and 2H2 (−107.18±8.89 kcal/mol) have lower binding energies (indicating stronger binding abilities) to RBD than ACE2 (−94.94±11.95 kcal/mol), while antibody S2E12 (−85.77±8.55 kcal/mol) exhibits a similar binding energy to ACE2. These findings confirm the reliability of our binding energy estimations using MM/GBSA calculation. The aptamer Ta, with a binding energy of −142.93±7.65 kcal/mol, has a significant lower binding energy than both ACE2 and the three antibodies, indicating a stronger binding ability of the aptamer Ta to the RBD. We further tested the binding ability of the aptamer Ta with a commercial neutralizing antibody (SinoBiological, Cat: 40592-R001, termed 40592-R001) that targets the RBD of the SARS-CoV-2 spike protein. The antibody 40592-R001 demonstrated high affinity for the RBD in our native gel protein-protein binding assays (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>). We then added the antibody 40592-R001 into a mixture of the aptamer Ta and RBD, monitoring the changes in the formation of aptamer-RBD complex via fluorescence intensity in the ESMA experiments. In principle, if the aptamer Ta binds more strongly to RBD than the antibody 40592-R001, the presence of the antibody should not disrupt the formation of the aptamer-RBD complex; otherwise, the amount of the aptamer-RBD complex would be reduced. Notably, the Ta-RBD complex formation remained unchanged after adding the antibody (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>), suggesting that the aptamer Ta indeed has a comparable binding compared to 40592-R001. These results also confirmed that the aptamer Ta binds to the same site on the RBD as the 40592-R001 antibody. In conclusion, the aptamer Ta presents a promising alternative, or at least a complementary approach, to conventional antibody-based neutralizing therapies against COVID-19. These findings prompt us to further optimize the aptamer Ta to enhance its binding ability to the RBD of the SARS-CoV-2 spike protein.</p>
</sec>
<sec id="s2d">
<label>2.4</label><title>Structure-based rational design of the aptamer Ta to improve binding affinity</title>
<p>Since the SELEX screening process explored only a limited sequence space, we anticipated that the SELEX-derived aptamer Ta could be further optimized <italic>via</italic> rational mutation scanning to improve its binding affinity to the RBD of the SARS-CoV-2 spike protein. In principle, nucleotide mutations in the aptamers can affect the binding affinity, which can be characterized by changes in binding free energy (ΔΔ<italic>G</italic>), and we accurately assessed these changes using FEP calculations. A negative change in binding free energy (ΔΔ<italic>G</italic>&lt;0) indicates improved binding affinity, while a positive change (ΔΔ<italic>G</italic>&gt;0) means a decrease in binding affinity. FEP is regarded as one of the most rigorous and reliable methods in estimating binding free energy changes, achieving high accuracy in identifying key residues and their mutational effects for many protein-protein, protein-ligand, and protein-RNA complexes, with results comparable with experiments [<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c37">37</xref>]. However, unlike protein and peptide drugs, the structure of RNA molecules is very sensitive to its nucleotide composition and even a single mutation may cause significant changes in its secondary (2D) structure, potentially affecting its binding modes. To address this, we employed secondary structure analysis (SSA) to examine the structural similarity before and after nucleotide mutation. Moreover, we used MFold [<xref ref-type="bibr" rid="c30">30</xref>] to predict the 2D structure with the lowest free energy for each mutated sequence. Structural similarity between the wild-type (WT) Ta sequence and its mutants was quantified by base-pair (BP) similarity, defined as the ratio of shared base pairs (<italic>N<sub>shared</sub></italic>) to the total base pairs in the WT sequence (<italic>N<sub>WT</sub></italic>). Overall, as summarized in <xref rid="fig4" ref-type="fig">Fig. 4A</xref>, we combined rational mutation scanning, SSA, and FEP to design Ta analogues with enhanced binding affinity.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 4.</label>
    <caption><title>Structure-based rational design of Ta analogues with improved binding affinities and their experimental validation.</title>
        <p>(A) Flowchart illustrating the combination of rational mutation scanning, secondary structure analysis (SSA), and free energy perturbation (FEP) to optimize aptamer binding affinities. (B) Contact ratios of nucleotides on the aptamer Ta bound to RBD (dark blue surface). Data were collected from three independent MD simulations. (C) SSA based on BP similarity for 16 selected nucleotides mutated to other three bases. Definition of BP similarity was given in the main text. Only mutations with BP similarity greater than 0.9 were subjected to further FEP calculations. (D) The binding free energy changes assessed by FEP calculations for selected single mutations. Data represent mean±s.d. collected from five independent simulations. (E) EMSA results of Ta, Tc, and 6 designed candidate sequences bound to the RBD of SARS-CoV-2 spike protein. The aptamer-RBD complex bands were detected by running an agarose gel after incubation of 40 μM of RBD protein with 5 μM indicated aptamer variant. (F) Comparison of the binding free energy changes derived from FEP calculations (ΔΔ<italic>G</italic>, left scale) and EMSA experiments (ΔΔ<italic>G<sub>exp</sub></italic>, right scale) for 6 designed candidate aptamers. Data represent mean±s.d. collected from 5 (FEP)/three (EMSA) independent replications.</p></caption>
<graphic xlink:href="657802v3_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Based on the binding complex between the aptamer Ta and RBD constructed above, we selected 16 vital nucleotides (A14, C23-G34, A40, and A42-G43) on the aptamer Ta that showed high contact frequency with RBD (see <xref rid="fig4" ref-type="fig">Fig. 4B</xref>) for exhaustive single-mutation scanning. These selected nucleotides play a crucial role in Ta-RBD binding interactions, and their mutagenesis studies may aid in designing analogues with improved binding affinity. After SSA based on BP similarity, we found that most single mutations preserved a WT-like 2D structure (<xref rid="fig4" ref-type="fig">Fig. 4C</xref>) with BP similarity greater than 0.9 (such as Ta<sup>G34C</sup> in Fig. S8), but several single mutations cause significant rearrangement of their 2D structure with a BP similarity less than 0.9 (for instance, Ta<sup>U30G</sup> in Fig. S8). Mutations with a BP similarity greater than 0.9 were subjected to FEP calculations to further evaluate their impact on binding free energy changes, with the results shown in <xref rid="fig4" ref-type="fig">Fig. 4D</xref> and Table S3.</p>
<p>For nucleotides in the apical loop of the aptamer Ta (see <xref rid="fig1" ref-type="fig">Figs. 1B</xref> and <xref rid="fig2" ref-type="fig">2E</xref>), mutation to any other base types resulted in an increased binding free energy and weakened binding affinity, such as ΔΔ<italic>G</italic>=1.94±0.43 kcal/mol for G25C, 0.66±0.16 kcal/mol for U27G, and 4.66±0.76 kcal/mol for C29G. This suggests that G25, U27 and C29 are already optimal choices for RBD binding. The previous study [<xref ref-type="bibr" rid="c16">16</xref>] highlighted the importance of the apical loop in directing the aptamer Ta’s binding to the RBD, and truncation of this apical loop was proven to significantly reduce its binding ability. Our FEP calculations align with this observation. Next, though the end stem part of the aptamer Ta also tightly binds to the RBD (see <xref rid="fig2" ref-type="fig">Figs. 2E</xref> and <xref rid="fig4" ref-type="fig">4B</xref>), base mutations in this region had minimal effects on binding affinity, likely due to dominant electrostatic interactions between the negatively charged phosphate groups and the positively charged residues of RBD. For instance, A42G showed a ΔΔ<italic>G of</italic> −0.22±0.56 kcal/mol and G43U a ΔΔ<italic>G</italic> of 0.37±0.30 kcal/mol. Furthermore, since the bulge part of the aptamer Ta serves as a linker to regulate the saddle-like binding shape with RBD (see <xref rid="fig2" ref-type="fig">Figs. 2E</xref> and <xref rid="fig4" ref-type="fig">4B</xref>), nucleotide mutations in this region may also affect binding ability despite their low contact frequency with the RBD. Indeed, disruption of the C23-G34 base pair improved the binding affinity of the aptamer to RBD, with C23A, C23G, and C23U yielding ΔΔ<italic>G</italic> values of −2.15±0.43, −2.49±0.49, and −1.96±0.58 kcal/mol, respectively, and G34A, G34C, and G34U showing ΔΔ<italic>G</italic> values of −2.50±0.28, −3.05± 0.26, and −2.65±0.33 kcal/mol, respectively (see <xref rid="fig4" ref-type="fig">Fig. 4D</xref> and Table S3). Ultimately, we generated six candidate sequences (Ta<sup>C23A</sup>, Ta<sup>C23G</sup>, Ta<sup>C23U</sup>, Ta<sup>G34A</sup>, Ta<sup>G34C</sup>, and Ta<sup>G34U</sup>) predicted to have stronger binding affinity to RBD than WT aptamer Ta.</p>
<p>We conducted EMSA experiments to validate the binding ability of these designed aptamers. Preliminary binding results of the RBD-RNA complex bands showed that five of the six designed sequences (Ta<sup>G34C</sup>, Ta<sup>G34U</sup>, Ta<sup>G34A</sup>, Ta<sup>C23A</sup>, and Ta<sup>C23U</sup>) exhibited higher fluorescence intensity than WT aptamer Ta (see <xref rid="fig4" ref-type="fig">Fig. 4E</xref>). Further, the binding curves with different RBD concentrations and the resulting dissociation constant (<italic>K<sub>d</sub></italic>) measurements confirmed the superior binding capabilities of these five sequences compared to WT aptamer Ta (see Fig. S9 and Table S2). As shown in <xref rid="fig4" ref-type="fig">Fig. 4F</xref>, except for Ta<sup>C23G</sup>, the binding free energy changes derived from EMSA experiments (ΔΔ<italic>G<sub>exp</sub></italic>) were consistent with FEP calculations (ΔΔ<italic>G</italic>) for the remaining five designed aptamers. Here, the experimental binding free energy change is <inline-formula id="inline-eqn-1"><inline-graphic xlink:href="657802v3_inline1.gif" mimetype="image" mime-subtype="gif"/></inline-formula>, where <inline-formula id="inline-eqn-2"><inline-graphic xlink:href="657802v3_inline2.gif" mimetype="image" mime-subtype="gif"/></inline-formula>and <inline-formula id="inline-eqn-3"><inline-graphic xlink:href="657802v3_inline3.gif" mimetype="image" mime-subtype="gif"/></inline-formula>are dissociation constants for WT aptamer Ta and the designed sequence, respectively, and k<sub>B</sub> is the Boltzmann constant and T = 310 K. The magnitude of the binding free energy changes generated from FEP calculations tend to be greater, likely due to limitations in the force field parameters. Nonetheless, the high success rate (0.83, 5/6) achieved in this structure-based rational design process underscores the reliability of the RBD-aptamer Ta complex model proposed in <xref rid="fig2" ref-type="fig">Fig. 2E</xref>. These results highlight the potential of our CAAMO framework as an effective tool for optimizing aptamer binding affinity.</p>
</sec>
<sec id="s2e">
<label>2.5</label><title>Designed aptamer Ta<sup>G34C</sup> shows excellent binding ability to RBD</title>
<p>Among the five designed candidate sequences, both the FEP calculation and EMSA experiment confirmed that aptamer Ta<sup>G34C</sup> has the highest binding affinity to the RBD of SARS-CoV-2 spike protein. As shown in <xref rid="fig5" ref-type="fig">Fig. 5A</xref>, the dissociation constant derived from EMSA experiments for aptamer Ta<sup>G34C</sup> is <italic>K<sub>d</sub></italic>=33.5±1.6 µM, which is approximately 3.3-fold higher compared to WT Ta (<italic>K<sub>d</sub></italic>=110.7 µM). The remaining four designed aptamers exhibited approximately a 2-fold increase in binding affinity relative to WT Ta, with <italic>K<sub>d</sub></italic>=55.5±4.1 µM for Ta<sup>G34A</sup> and <italic>K<sub>d</sub></italic>=55.7±9.8 µM for Ta<sup>C23A</sup> (see Fig. S9 and Table S2).</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 5.</label>
    <caption><title>Designed aptamer Ta<sup>G34C</sup> showed superior binding ability than WT Ta or antibody.</title>
        <p>(A) Binding curves and the resultant dissociation constants (<italic>K<sub>d</sub></italic>) for WT Ta and the designed Ta<sup>G34C</sup> with RBD proteins. The <italic>K<sub>d</sub></italic> values were calculated from the EMSA image quantification with s.d. from three independent experiments. (B) Comparison of the Ta-RBD and Ta<sup>G34C</sup>-RBD binding complexes. RNA is shown as a dark red ribbon while RBD is displayed as a dark blue surface. Zoom-in is the nucleotide G34 (WT Ta)/C34 (Ta<sup>G34C</sup>) and its surrounding nucleotide U35 and residue PHE486 shown in sticks. Atoms oxygen and nitrogen are colored in red and blue, respectively, and carbon atoms are colored by their locations. Definitions of two related distances (D1 and D2) are also displayed. (C) Violin plots of distributions of two related distances (D1 and D2) between selected RNA nucleotide-protein residue in Ta-RBD and Ta<sup>G34C</sup>-RBD binding complexes, respectively. Data were collected from three independent MD simulations. (D) EMSA images of competitive binding experiments to characterize the RBD binding abilities of RNA aptamers (WT Ta and Ta<sup>G34C</sup>) and the commercial monoclonal SARS-CoV-2 neutralizing antibody 40592-R001. The aptamer-RBD complex bands were showed by running an agarose gel after incubation of 40 μM of RBD protein and indicated aptamer with varying concentrations of the antibody 40592-R001. Results showed that Ta<sup>G34C</sup>, but not WT Ta, exhibited a higher binding affinity to the RBD proteins than that of the antibody.</p></caption>
<graphic xlink:href="657802v3_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We performed MD simulations on the Ta<sup>G34C</sup>-RBD binding complex to explore the molecular mechanism underlying the improved binding affinity of aptamer Ta<sup>G34C</sup>. As shown in the <xref rid="fig5" ref-type="fig">Fig. 5B</xref>, the C23-G34 base pair is located in the bulge region of WT Ta, which plays a critical role in regulating its saddle-like binding shape. We speculated that disrupting the C23-G34 base pair through mutation (e.g., G34C) could reduce the strain during aptamer binding to the RBD. The G34C substitution can alter the binding environment of adjacent nucleotides, such as U35, allowing them to form tighter contacts with the RBD loop region (from GLN474 to TYR489). For instance, our simulations showed that the distance between nucleotide U35 and PHE486 is shorter in the Ta<sup>G34C</sup>-RBD complex than that in the WT Ta-RBD complex (see <xref rid="fig5" ref-type="fig">Fig. 5C</xref>). This reduced distance remains stable throughout the MD simulations, indicating that U35 and PHE486 form a stable π-π stacking interaction after the G34C substitution. Additionally, the distance between C34 and PHE486 in Ta<sup>G34C</sup>-RBD is also closer compared to G34 and PHE486 in WT Ta-RBD. These findings support our hypothesis regarding the improved binding affinity in aptamer Ta<sup>G34C</sup> and provide a basis for further in silico design of new aptamers.</p>
<p>We also conducted competitive binding experiments to compare the binding capacities of the designed aptamer Ta<sup>G34C</sup> and a commercial monoclonal SARS-CoV-2 neutralizing antibody [<xref ref-type="bibr" rid="c38">38</xref>] against the RBD. As shown in <xref rid="fig5" ref-type="fig">Fig. 5D</xref> and <xref rid="fig1" ref-type="fig">Fig. 1F</xref>, when the monoclonal SARS-CoV-2 neutralizing antibody 40592-R001 was added to the WT Ta-RBD complex, the fluorescence intensity of the complex band gradually decreased, indicating that the antibody at high concentrations can partially replace the aptamer Ta in the Ta-RBD binding complex and has comparable, though weaker, binding ability. However, when the same antibody was added to the designed Ta<sup>G34C</sup>-RBD complex, the fluorescence intensity of the complex bands remained nearly unchanged at all tested antibody concentrations, indicating that the binding affinity of Ta<sup>G34C</sup> is significantly stronger than that of the monoclonal SARS-CoV-2 neutralizing antibody or WT aptamer Ta.</p>
<p>In summary, the combined results from FEP calculated and EMSA measured binding affinities, binding molecular mechanism analysis, and antibody competitive binding assays clearly demonstrate that the designed aptamer Ta<sup>G34C</sup> exhibits excellent binding ability to RBD. These findings highlight the importance of optimizing SELEX-derived aptamers through structure-based rational design to enhance their binding affinity.</p>
</sec>
<sec id="s2f">
<label>2.6</label><title>Binding performance of Ta and Ta<sup>G34C</sup> against SARS-CoV-2 RBD variants</title>
<p>To further evaluate the binding performance and specificity of the designed aptamer Ta<sup>G34C</sup> toward different SARS-CoV-2 variants [<xref ref-type="bibr" rid="c39">39</xref>], we conducted extensive free energy perturbation combined with Hamiltonian replica-exchange molecular dynamics (FEP/HREX) [<xref ref-type="bibr" rid="c40">40</xref>–<xref ref-type="bibr" rid="c42">42</xref>] for both the wild-type aptamer Ta and the optimized Ta<sup>G34C</sup> against a series of RBD mutants. The representative variants include the early Alpha (B.1.1.7) and Beta (B.1.351) lineages, as well as a panel of Omicron sublineages (BA.1–BA.5, BA.2.75, BQ.1, XBB, XBB.1.5, EG.5.1, HK.3, JN.1, and KP.3) carrying multiple mutations within the RBD region (residues 333–527). For each variant, mutations within 5 Å of the bound aptamer were included in the FEP to accurately estimate the relative binding free energy change (ΔΔ<italic>G</italic>).</p>
<p>For the wild-type Ta aptamer, the FEP-predicted binding affinities toward the Alpha and Beta RBD variants were consistent with the previous experimental results, further validating the reliability of our model (see Table S4). Specifically, Ta maintained comparable or slightly enhanced binding to the Alpha variant and showed only marginally reduced affinity for the Beta variant.</p>
<p>In contrast, the optimized aptamer Ta<sup>G34C</sup> exhibited markedly improved and broad-spectrum binding capability toward most tested variants (see Table S5). For early variants such as Alpha, Beta, and Gamma, Ta<sup>G34C</sup> maintained enhanced affinities (ΔΔ<italic>G</italic> &lt; 0). Notably, for multiple Omicron sublineages—including BA.1, BA.2, BA.2.12.1, BA.2.75, XBB, XBB.1.5, XBB.1.16, XBB.1.9, XBB.2.3, EG.5.1, XBB.1.5.70, HK.3, BA.2.86, JN.1 and JN.1.11.1—the calculated binding free energy changes ranged from −1.89 to −7.58 kcal/mol relative to the wild-type RBD, indicating substantially stronger interactions despite the accumulation of multiple mutations at the aptamer–RBD interface. Only in a few other Omicron sublineages, such as BA.4, BA.5, and KP.3, a slight reduction in binding affinity was observed (ΔΔ<italic>G</italic> &gt; 0).</p>
<p>These computational findings demonstrate that the Ta<sup>G34C</sup> aptamer not only preserves high affinity for the RBD but also exhibits improved tolerance to the extensive mutational landscape of SARS-CoV-2. Collectively, our results suggest that Ta<sup>G34C</sup> holds promise as a high-affinity and potentially cross-variant aptamer candidate for targeting diverse SARS-CoV-2 spike protein variants, showing potential for broad-spectrum antiviral activity.</p>
</sec>
</sec>
<sec id="s3">
<label>3.</label><title>Discussion and conclusion</title>
<p>Determining the 3D structure of RNA aptamer-target protein complexes is crucial for understanding the binding mechanism and optimizing binding efficacy for various applications. Despite the discovery of aptamers for over 1,100 target proteins [<xref ref-type="bibr" rid="c43">43</xref>], only a limited number of aptamer-protein complex 3D structures are available (only 119 deposited in the PDB). The scarcity of experimentally determined aptamer-protein structures is primarily due to the inherent flexibility of RNA molecules and the high cost of experimental procedures. However, with recent advancement in protein and RNA 3D structure prediction [<xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c44">44</xref>,<xref ref-type="bibr" rid="c45">45</xref>] and improvements in atomic force field parameters [<xref ref-type="bibr" rid="c46">46</xref>,<xref ref-type="bibr" rid="c47">47</xref>], as well as the increased availability of high-performance computing resources, computational modeling of RNA aptamer-protein complexes has become increasingly promising. In this work, we developed a multi-strategy computational approach to determine the most probable RNA aptamer-protein binding conformation. Our approach integrates RNA 3D structure prediction, ensemble docking, clustering, and binding capacity assessment, with a critical focus on identifying the lowest-energy binding conformation using various energy assessment methods. We believe that the predicted binding conformation reliably represents the closest approximation among the predicted ensemble, although it may not perfectly mimic the native structure conformation in all systems.</p>
<p>We found that the aptamer Ta binds to the RBD of SARS-CoV-2 spike protein in a saddle-like shape, where the apical loop and end stem parts bind to two opposite sides of the RBD, while the bulge serves as a connector and regulates the bending angle. Theoretical analysis and experimental validation confirmed that this binding model is reliable. With this 3D structure, we were able to conduct structure-based rational optimization of the aptamer sequence to improve its binding affinity and then to perform a head-to-head comparison between the RNA aptamer and neutralizing antibodies.</p>
<p>The development of aptamer-based RNA therapeutics involves iterative rounds of design, testing, and optimization. A key step in this process is optimizing the original aptamer sequence to design a series of analogues with comparable or even improved binding affinities to the target protein. <italic>In silico</italic> structure-based aptamers design, which involves nucleotide mutation, insertion, deletion and their binding affinity assessment, is gaining prominence [<xref ref-type="bibr" rid="c48">48</xref>]. Our proposed framework, CAAMO, enables efficient aptamer lead optimization requiring only the aptamer’s nucleotide sequence as the input information. Unlike peptide and protein counterparts, RNA structures are highly sensitive to nucleotide composition, and even a single mutation may cause rearrangement in its secondary structure. To address this issue, we employed secondary structure analysis to evaluate the effect of mutations on RNA folding and only submitted those maintaining a similar folding structure to subsequent FEP-guided binding free energy evaluations.</p>
<p>For the Ta-RBD binding complex, mutation scanning revealed that mutations of nucleotides in direct contact with the RBD showed negligible or increased binding free energy changes, whereas mutations in the middle portion, which has fewer contacts with RBD but regulates the bending angle of RNA aptamer, resulted in reduced binding free energy and improved binding affinity. These findings suggest that during structure-based optimization, attention should be paid not only to the nucleotides at the binding interface but also to the regulatory nucleotides that affect the binding shape. Our CAAMO framework generated six optimized candidate sequences, and EMSA experiments confirmed that five of them exhibited significantly stronger binding affinity to the RBD than the wild-type Ta (about 2 to 3.3-fold improvement). This high success rate (∼83%) validates the reliability of the putative 3D binding model and demonstrates the effectiveness of our computational framework. Although the absolute <italic>K<sub>d</sub></italic> values determined by EMSA cannot be directly compared with surface-based methods such as SPR or BLI, the relative affinity trends remain highly consistent. While EMSA provides semi-quantitative affinity estimates, the close agreement between experimental EMSA trends and FEP-calculated ΔΔ<italic>G</italic> values supports the robustness of the relative affinity changes reported here. In future studies, additional orthogonal biophysical techniques (e.g., filter-binding, SPR, or BLI) will be employed to further validate and refine the protein–aptamer interaction models. Furthermore, since the current study only considered single-nucleotide mutations, other design strategies such as double mutations, multiple mutations, nucleotide insertions and deletions should be explored in the future studies. In addition to the Ta–RBD system, the CAAMO framework itself is inherently generalizable. More work is currently underway to apply CAAMO to optimize aptamers targeting other therapeutically relevant proteins, such as the epidermal growth factor receptor (EGFR) [<xref ref-type="bibr" rid="c49">49</xref>], in order to further explore its potential for broader aptamer engineering. While the present study primarily focused on affinity optimization, we acknowledge that other key developability traits—such as nuclease resistance, structural and thermodynamic stability, and in vivo persistence—are equally critical for advancing aptamers toward therapeutic applications. These properties were not evaluated here but will be systematically addressed in future iterations of the CAAMO framework to enable comprehensive optimization of aptamer candidates.</p>
<p>Aptamers, often referred to as “chemical antibody”, offer a valuable comparison to real antibodies in terms of binding properties, yet such comparative analyses are currently limited. The RBD of SARS-CoV-2 spike protein is an ideal target for these comparisons, as binding modes for both the aptamer Ta and neutralizing antibody-RBD complexes are available. Our computational and experimental studies showed that the aptamer Ta has comparable binding abilities to the RBD compared to popular neutralizing antibodies. Analysis of the underlying binding details revealed that more critical RBD residues are involved in aptamer Ta-RBD interaction, while MM/GBSA calculations and competitive binding assays confirmed the stronger binding capacity of the aptamer Ta. Specifically, a newly designed aptamer (Ta<sup>G34C</sup>) exhibited excellent RBD binding ability, surpassing both WT Ta and commercial antibodies. Given the concerns surrounding antibody-dependent enhancement (ADE), which could worsen COVID-19 outcomes by increasing virus infectivity and virulence [<xref ref-type="bibr" rid="c50">50</xref>], there is an urgent need to develop smaller and safer molecules to neutralize the virus and complement existing treatment modalities. Furthermore, the previous study [<xref ref-type="bibr" rid="c16">16</xref>] has claimed that WT Ta aptamer can efficiently block viral infection at low concentration and provide a promising lead for the detection and treatment of SARS-CoV-2 and emerging variants. Therefore, the designed aptamer Ta<sup>G34C</sup>, as well as other four successful candidates, provides a promising alternative to antibodies for fighting COVID-19.</p>
</sec>
<sec id="s4">
<label>4.</label><title>Materials and Methods</title>
<sec id="s4a">
<label>4.1</label><title>Generation of aptamer 3D conformation ensemble</title>
<p>To predict the 3D structures of the aptamers Ta (5’-GGCGACAUUU GUAAUUCCUG GACCGAUACU UCCGUCAGGA CAGAGGUUGC CA-3’) and Tc (5’-GGUCCUGGAC CGAUACUUCC GUCAGGACCA-3’), five state-of-the-art RNA 3D structure prediction tools were employed: IsRNA2 [<xref ref-type="bibr" rid="c32">32</xref>], FARFAR2 [<xref ref-type="bibr" rid="c31">31</xref>], SimRNA [<xref ref-type="bibr" rid="c33">33</xref>], iFoldRNA [<xref ref-type="bibr" rid="c51">51</xref>], and RNAComposer [<xref ref-type="bibr" rid="c52">52</xref>]. The predicted secondary structure from Mfold [<xref ref-type="bibr" rid="c30">30</xref>], along with the aptamer sequence, were used as input for 3D structure prediction. IsRNA2 was downloaded and ran locally following the identical procedure as in the previous studies [<xref ref-type="bibr" rid="c53">53</xref>]; FARFAR2 was executed in Rosetta 3.12 using the <italic>rna_denovo</italic> application with default parameters; web-based version of SimRNA, iFoldRNA, and RNAComposer were assessed, and their default parameters were used. The top 5 predictions generated by each program (25 structures in total) were collected to construct a 3D conformation ensemble of a given RNA aptamer.</p>
</sec>
<sec id="s4b">
<label>4.2</label><title>Generation of aptamer-RBD binding complex pool</title>
<p>The binding complex pool for aptamer Ta-RBD was generated using multiple popular docking tools, including HADDOCK [<xref ref-type="bibr" rid="c54">54</xref>], HDOCK [<xref ref-type="bibr" rid="c55">55</xref>], ZDOCK [<xref ref-type="bibr" rid="c56">56</xref>], and RosettaDock [<xref ref-type="bibr" rid="c57">57</xref>]. Rosettadock was performed locally using Rosetta software, while the other three docking tasks were completed on their respective webservers. The RBD structure [<xref ref-type="bibr" rid="c23">23</xref>] (PDB id: 6LZG) refined by MD simulation, and 25 RNA 3D conformations predicted in the previous step were used as the receptor and ligands for docking, respectively. The top 10 binding poses from each docking were recorded, yielding a total of 1,000 (4×25×10) aptamer Ta-RBD binding complexes in the pool. Of these, 879 conformations shared the same binding interface of ACE2-RBD complex. Then, these 879 conformations were clustered into 6 major groups, each representing a significantly distinct binding conformation. The binding complex pool for Tc-RBD interaction (used as a negative control) was constructed following the same procedure.</p>
</sec>
<sec id="s4c">
<label>4.3</label><title>Molecular dynamics simulations</title>
<p>All-atom MD simulations were performed using Gromacs [<xref ref-type="bibr" rid="c58">58</xref>] (version 2021.5). For each system, a water box with at least 1.5 nm distance from the surface of the complex was used to solvate the systems, and NaCl ions were added to achieve a physiological concentration of 150 mM after neutralizing the system. The Amberff14SB force field was used for protein and RNA. Water molecules were described by TIP3P model [<xref ref-type="bibr" rid="c59">59</xref>] and Li and Merz ion parameters [<xref ref-type="bibr" rid="c60">60</xref>] were used. The periodic boundary conditions were applied in all three dimensions. The particle mesh Ewald (PME) method was used to compute the long-range electrostatic interactions while the vdW interactions were truncated at 1.5 nm. The LINCS algorithm was adopted to constrain the H-bonds to allow an integration timestep of 2 fs. Before MD productions, an energy minimization, 100 ps NVT, and 10 ns NPT simulations with a temperature of T = 310.15 K and pressure of 1 atm was executed sequentially to equilibrate the simulation box. To prevent unexpected structural deviations in the beginning, position restraints on backbone atoms of RNA and protein were performed in the NVT and NPT simulations. After that, series of MD simulations were conducted in the NPT ensemble with velocity-rescaled Berendsen thermostat: (1) 500ns MD simulations were performed for the RBD. Snapshots extracted from the last 300 ns MD trajectories (600 snapshots recorded in the duration of 500 ps) were clustered based on linkage method with a 0.2 nm RMSD cutoff to obtain the most probable receptor conformation for docking. (2) 100 ns simulations were performed on the representative Ta/Tc-RBD complex conformations obtained from the docking. 5 mM MgCl<sub>2</sub> was added to the simulation system. These trajectories were used to calculate RMSD and MM/GBSA. (3) 100 ns simulations were performed on the ACE2-RBD complex (PDBID: 6LZG) and three antibody-RBD complexes (PDBID: 7CDI, 7DK4 and 7K4N). These also were used to perform MM/GBSA. (4) 500ns simulations were conducted for the Ta<sup>G34C</sup>-RBD and Ta-RBD complexes. 5 mM MgCl<sub>2</sub> was added to the simulation system. A summary of MD simulations performed in this study was given in Table S1. The 3D structure models were rendered using UCSF ChimeraX (version 1.6.1) programs.</p>
</sec>
<sec id="s4d">
<label>4.4</label><title>MM/GBSA calculations</title>
<p>In this study, binding energies (Δ<italic>G</italic>) of ACE2, aptamers (Ta and Tc), and several neutralizing antibodies to RBD were assessed using the end-point Molecular Mechanics Generalized Born Surface Area (MM/GBSA) method, implemented through the gmx_MMPBSA software [<xref ref-type="bibr" rid="c61">61</xref>]. Briefly, Δ<italic>G</italic> was calculated by summing up the changes in electro-static energies (Δ<italic>E<sup>ele</sup></italic>), the van der Waals energies (Δ<italic>E<sup>vdW</sup></italic>), the electrostatic solvation energy (Δ<italic>G<sup>GB</sup></italic>, polar contribution), the nonpolar contribution (Δ<italic>G<sup>SA</sup></italic>) between the solute and the continuum solvent, and conformational entropy (<italic>–T</italic>Δ<italic>S</italic>) upon ligand binding. The dielectric constants for the solute and solvent were set to 10 and 78.5, respectively. The OBC solvation model (igb = 8) was used. The interaction entropy method was used to calculate the conformational entropy (<italic>–T</italic>Δ<italic>S</italic>). Additionally, the lowest energy conformations from the complexes pool clustering were selected based on single-frame conformational MM/GBSA. The static complex structure was employed to calculate the enthalpy using MM/GBSA.</p>
</sec>
<sec id="s4e">
<label>4.5</label><title>SMD and rupture works</title>
<p>Constant velocity steered molecular dynamics (SMD) was performed to calculate the rupture work required to separate the bound aptamer from the RBD. A steered velocity of 0.1 nm/ns was applied to the center-of-mass (COM) of the aptamer, while keeping the COM of RBD fixed, using the COM distance between aptamer (or antibody) and RBD as the collective variable. Four replicate SMD simulations (about 50 ns simulation time each) were performed for each binding complex. All simulation parameters remain the same as those used in the MD simulations. The force spectra were recorded during the SMD simulations at a 0.1 ps intervals. The rupture works were obtained through integration of the force spectra over the COM distance.</p>
</sec>
<sec id="s4f">
<label>4.6</label><title>FEP calculations</title>
<p>The binding free energy changes resulting from point mutations of key bases at the interface between the aptamer Ta and RBD were calculated using the free energy perturbation (FEP) method. We estimated the binding free energy changes for single nucleotide mutation in both the bound state (Ta and RBD complex) Δ<italic>G<sub>bound</sub></italic> and the free state (the aptamer Ta only) Δ<italic>G<sub>free</sub></italic> using Gromacs 2021.5. Thus, the binding free energy change caused by nucleotide mutation was estimated as ΔΔ<italic>G<sub>calc</sub></italic>=Δ<italic>G<sub>bound</sub></italic>-Δ<italic>G<sub>free</sub></italic>. For each single nucleotide mutation, the dual-topology file was prepared in a pmx-like manner based on the Amberff14SB force field and eighteen λ windows (0.0, 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75, 0.8, 0.85, 0.9, 0.95, 0.99, and 1.0) with 1 ns/window were used. The vdW and electrostatic interactions were transferred simultaneously during simulations and the soft-core potentials (α=0.3) were used. For each mutation, five independent replicas starting from different conditions were performed for sufficient sampling and at least 180 ns (1 ns×18 windows×5 runs×2 states) simulation time was generated, which result in reasonable convergence in the free energy calculations. The Gromacs bar analysis tool was used to estimate the binding free energy changes.</p>
</sec>
<sec id="s4g">
<label>4.7</label><title>FEP/HREX</title>
<p>To evaluate the binding sensitivity of the optimized aptamer Ta<sup>G34C</sup> toward SARS-CoV-2 RBD variants, we employed free energy perturbation combined with Hamiltonian replica-exchange molecular dynamics (FEP/HREX) simulations for enhanced sampling efficiency and improved convergence. The relative binding free energy changes (ΔΔ<italic>G</italic>) upon RBD mutations were estimated as:
<disp-formula id="disp-eqn-1">
<graphic xlink:href="657802v3_ueqn1.gif" mimetype="image" mime-subtype="gif"/>
</disp-formula>
where Δ<italic>G<sub>bound</sub></italic>and Δ<italic>G<sub>free</sub></italic>represent the RBD mutations-induced free energy changes in the complexed and unbound states, respectively. All simulations were performed using GROMACS 2021.5 with the Amber ff14SB force field. For each mutation, dual-topology structures were generated in a pmx-like manner, and 32 λ-windows (0.0, 0.01, 0.02, 0.03, 0.06, 0.09, 0.12, 0.16, 0.20, 0.24, 0.28, 0.32, 0.36, 0.40, 0.44, 0.48, 0.52, 0.56, 0.60, 0.64, 0.68, 0.72, 0.76, 0.80, 0.84, 0.88, 0.91, 0.94, 0.97, 0.98, 0.99, 1.0) were distributed uniformly between 0.0 and 1.0. To ensure sufficient sampling, each window was simulated for 5 ns, with five independent replicas initiated from distinct velocity seeds. Replica exchange between adjacent λ states was attempted every 1 ps to enhance phase-space overlap and sampling convergence. The van der Waals and electrostatic transformations were performed simultaneously, employing a soft-core potential (α = 0.3) to avoid singularities. For each RBD variant system, this setup resulted in an accumulated simulation time of approximately 1600 ns (5 ns × 32 windows × 5 replicas × 2 states). The Gromacs bar analysis tool was used to estimate the binding free energy changes.</p>
</sec>
<sec id="s4h">
<label>4.8</label><title>EMSA experiments</title>
<p>The sequences of Ta, Tc, Ta<sup>G34C</sup>, Ta<sup>G34U</sup>, Ta<sup>G34A</sup>, Ta<sup>C23G</sup>, Ta<sup>C23A</sup>, and Ta<sup>C23U</sup> aptamers are shown in Table S2. In these sequences, the uppercase letters A, U, G and C indicated the ribonucleotide. The EMSA was performed according to a previous protocol [<xref ref-type="bibr" rid="c53">53</xref>] with a minor modification. Synthesized 5′ end Cy3-labelled RNAs were resuspended with the RNase-free H<sub>2</sub>O to a concentration of 100 µM. 5 μl of Cy3-labelled RNAs were annealed with the 5 μl 2×annealing buffer (20 mM Tris-HCl pH 7.5, 200 mM KCl) under a predefined procedure: 68°C for 5min, then annealing at −0.1°C/s to 25°C, and finally at 25°C for 5 min, then diluted to the final concentration of 5 µM. The SARS-CoV-2 Spike RBD protein was purchased from HuaBio (Cat: HA210064). Mouse monoclonal SARS-CoV-2 neutralizing antibody was purchased from Sino Biological (Cat: 40592-R001). 40 μM of RBD protein and 5 μM of annealed Cy3-labelled aptamers were mixed in the EMSA buffer (10 mM Sodium phosphate buffer pH 7.5, 1 U/μl SUPERase-In RNase Inhibitor [Thermo Fisher]). Mixtures were incubated at room temperature for 20 min.</p>
<p>For competitive binding experiments, 40 μM of RBP proteins, 5 μM of annealed Cy3-labelled RNAs and increasing concentrations of SARS-CoV-2 neutralizing antibody 40592-R001 (0–1.67 μM) were mixed in the EMSA buffer and incubated at room temperature for 20 min. Next, the mixtures were added 6×loading buffer (15% Ficoll 400, 0.25% Bromophenol Blue, 0.25% Xylene cyanol, 1×TBE), then resolved on a native 0.8% agarose gel and imaged with iBright1500 (Thermo Fisher). The images were quantified with Image J software. The dissociation constant <italic>K<sub>d</sub></italic> for RBD with aptamers were calculated using Prism 8 (GraphPad) software.</p>
</sec>
</sec>

</body>
<back>
<sec id="das" sec-type="data-availability">
<title>Data availability</title>
<p>The current manuscript is a computational study, all data are included in the main text and the supplemental data.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank Zaixing Yang and Teng Xie for their helpful discussions. This work was supported by funds from the National Key R&amp;D Program of China (2021YFF1200404 to R.Z., 2024YFA1307502 to D.Z.), National Natural Science Foundation of China (Nos. 12474203 to D.Z., U1967217 to R.Z.), the Zhejiang Provincial Natural Science Foundation of China (No. LZ25A040001 to D.Z.), National Independent Innovation Demonstration Zone Shanghai Zhangjiang Major Projects (ZJZX2020014 to R.Z.), Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University (SN-ZJU-SIAS-003 to R.Z., SN-ZJU-SIAS-006 to L.H., SN-ZJU-SIAS-009 to D.Z.), National Center of Technology Innovation for Biopharmaceuticals (NCTIB2022HS02010 to R.Z.), Shanghai Artificial Intelligence Lab (P22KN00272 to R.Z.), and Zhejiang University Global Partnership Fund (188170+194452409/004 to R.Z.).</p>
</ack>
<sec id="additional-info" sec-type="additional-information">
<title>Additional information</title>
<sec id="s5">
<title>CRediT authorship contribution statement</title>
<p>R.Z. designed research; Y.Y., and Y.J. performed all molecular simulations; L.Q. performed EMSA experiments under the supervision of Z.W.; Y.Y. contributed new reagents/analytic tools; Y.Y., Z.W., D.Z., and R.Z. analyzed data; Y.Y., L.Q., Z.W., D.Z., D.B., L.H., and R.Z. wrote the paper with contributions from all authors.</p>
</sec>
</sec>
<sec id="additional-files" sec-type="supplementary-material">
<title>Additional files</title>
<supplementary-material id="supp1">
<label>Supplemental Tables and Figures</label>
<media xlink:href="supplements/657802_file02.docx"/>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.D.</given-names> <surname>Ellington</surname></string-name>, <string-name><given-names>J.W.</given-names> <surname>Szostak</surname></string-name></person-group>, <article-title>In vitro selection of RNA molecules that bind specific ligands</article-title>, <source>Nature</source> <volume>346</volume> (<year>1990</year>) <fpage>818</fpage>–<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1038/346818a0</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names> <surname>Tuerk</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Gold</surname></string-name></person-group>, <article-title>Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase</article-title>, <source>Science</source> <volume>249</volume> (<year>1990</year>) <fpage>505</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1126/science.2200121</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.D.</given-names> <surname>Keefe</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Pai</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Ellington</surname></string-name></person-group>, <article-title>Aptamers as therapeutics</article-title>, <source>Nat. Rev. Drug Discov.</source> <volume>9</volume> (<year>2010</year>) <fpage>537</fpage>–<lpage>550</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3141</pub-id>.</mixed-citation></ref>
<ref id="c4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Wilson</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Hebbard</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Duan</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Liddle</surname></string-name>, <string-name><given-names>J.</given-names> <surname>George</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Qiao</surname></string-name></person-group>, <article-title>Aptamers: A promising chemical antibody for cancer therapy</article-title>, <source>Oncotarget</source> <volume>7</volume> (<year>2016</year>) <fpage>13446</fpage>–<lpage>13463</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.7178</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zu</surname></string-name></person-group>, <article-title>A highlight of recent advances in aptamer technology and its application</article-title>, <source>Molecules</source> <volume>20</volume> (<year>2015</year>) <fpage>11959</fpage>–<lpage>11980</lpage>. <pub-id pub-id-type="doi">10.3390/molecules200711959</pub-id>.</mixed-citation></ref>
<ref id="c6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.-K.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>C.-X.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>Y.-F.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Nan</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Nan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Kon</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.-Y.</given-names> <surname>Wei</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Su</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wei</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Peng</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Ad-El</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Peer</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>L.-L.</given-names> <surname>Chen</surname></string-name></person-group>, <article-title>Therapeutic application of circular RNA aptamers in a mouse model of psoriasis</article-title>, <source>Nat. Biotechnol</source>. (<year>2024</year>) <fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-024-02204-4</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.P.</given-names> <surname>Dassie</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>G.S.</given-names> <surname>Thomas</surname></string-name>, <string-name><given-names>R.M.</given-names> <surname>Whitaker</surname></string-name>, <string-name><given-names>K.W.</given-names> <surname>Thiel</surname></string-name>, <string-name><given-names>K.R.</given-names> <surname>Stockdale</surname></string-name>, <string-name><given-names>D.K.</given-names> <surname>Meyerholz</surname></string-name>, <string-name><given-names>A.P.</given-names> <surname>McCaffrey</surname></string-name>, <string-name><given-names>J.O.</given-names> <surname>McNamara</surname></string-name>, <string-name><given-names>P.H.</given-names> <surname>Giangrande</surname></string-name></person-group>, <article-title>Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors</article-title>, <source>Nat. Biotechnol</source>. <volume>27</volume> (<year>2009</year>) <fpage>839</fpage>–<lpage>846</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1560</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Rossi</surname></string-name></person-group>, <article-title>Aptamers as targeted therapeutics: current potential and challenges</article-title>, <source>Nat. Rev. Drug Discov</source>. <volume>16</volume> (<year>2017</year>) <fpage>181</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2016.199</pub-id>.</mixed-citation></ref>
<ref id="c9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Abatemarco</surname></string-name>, <string-name><given-names>M.F.</given-names> <surname>Sarhan</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Wagner</surname></string-name>, <string-name><given-names>J.-L.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Hassouneh</surname></string-name>, <string-name><given-names>S.-F.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>H.S.</given-names> <surname>Alper</surname></string-name>, <string-name><given-names>A.R.</given-names> <surname>Abate</surname></string-name></person-group>, <article-title>RNA-aptamers-in-droplets (RAPID) high-throughput screening for secretory phenotypes</article-title>, <source>Nat. Commun</source>. <volume>8</volume> (<year>2017</year>) <fpage>332</fpage>–<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-017-00425-7</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names> <surname>Ning</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Lu</surname></string-name></person-group>, <article-title>Aptamers used for biosensors and targeted therapy</article-title>, <source>Biomed Pharmacother</source>. <volume>132</volume> (<year>2020</year>) <fpage>110902</fpage>–<lpage>110922</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2020.110902</pub-id>.</mixed-citation></ref>
    <ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Eyetech Study Group</collab></person-group>, <article-title>Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results</article-title>, <source>Ophthalmology</source> <volume>110</volume> (<year>2003</year>) 979–986. <pub-id pub-id-type="doi">10.1016/S0161-6420(03)00085-X</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Jacobson</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Niu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Chen</surname></string-name></person-group>, <article-title>Combinatorial screening of DNA aptamers for molecular imaging of HER2 in cancer</article-title>, <source>Bioconjug Chem</source>. <volume>28</volume> (<year>2017</year>) <fpage>1068</fpage>–<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00746</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.-L.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.-L.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>X.-L.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zou</surname></string-name>, <string-name><given-names>H.-T.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>J.-J.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>P.-S.</given-names> <surname>Yao</surname></string-name>, <string-name><given-names>R.-J.</given-names> <surname>Pan</surname></string-name>, <string-name><given-names>C.J.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>D.-Z.</given-names> <surname>Kang</surname></string-name></person-group>, <article-title>Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity</article-title>, <source>Biochem. Biophys. Res. Commun</source>. <volume>453</volume> (<year>2014</year>) <fpage>681</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.09.023</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.E.</given-names> <surname>Lupold</surname></string-name>, <string-name><given-names>B.J.</given-names> <surname>Hicke</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>D.S.</given-names> <surname>Coffey</surname></string-name></person-group>, <article-title>Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen1</article-title>, <source>Cancer Res</source>. <volume>62</volume> (<year>2002</year>) <fpage>4029</fpage>–<lpage>4033</lpage>.</mixed-citation></ref>
<ref id="c15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names> <surname>Fang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name></person-group>, <article-title>Advances in COVID-19 mRNA vaccine development</article-title>, <source>Signal Transduct Target Ther</source>. <volume>7</volume> (<year>2022</year>) <fpage>1</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/s41392-022-00950-y</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Valero</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Civit</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Dupont</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Selnihhin</surname></string-name>, <string-name><given-names>L.S.</given-names> <surname>Reinert</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Idorn</surname></string-name>, <string-name><given-names>B.A.</given-names> <surname>Israels</surname></string-name>, <string-name><given-names>A.M.</given-names> <surname>Bednarz</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Bus</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Asbach</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Peterhoff</surname></string-name>, <string-name><given-names>F.S.</given-names> <surname>Pedersen</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Birkedal</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Wagner</surname></string-name>, <string-name><given-names>S.R.</given-names> <surname>Paludan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Kjems</surname></string-name></person-group>, <article-title>A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry</article-title>, <source>Proc. Natl. Acad. Sci</source>. <volume>118</volume> (<year>2021</year>) <fpage>e2112942118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2112942118</pub-id>.</mixed-citation></ref>
<ref id="c17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.H.</given-names> <surname>El-Nabi</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Elhiti</surname></string-name>, <string-name><given-names>M.</given-names> <surname>El-Sheekh</surname></string-name></person-group>, <article-title>A new approach for COVID-19 treatment by micro-RNA</article-title>, <source>Med. Hypotheses</source> <volume>143</volume> (<year>2020</year>) <fpage>110203</fpage>–<lpage>110205</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2020.110203</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>Y.-C.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>C.-F.</given-names> <surname>Shen</surname></string-name>, <string-name><given-names>C.-M.</given-names> <surname>Cheng</surname></string-name></person-group>, <article-title>Point-of-care RNA-based diagnostic device for COVID-19</article-title>, <source>Diagnostics</source> <volume>10</volume> (<year>2020</year>) <fpage>165</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.3390/diagnostics10030165</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Qin</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Qu</surname></string-name></person-group>, <article-title>Recent progress of SELEX methods for screening nucleic acid aptamers</article-title>, <source>Talanta</source> <volume>266</volume> (<year>2024</year>) <fpage>124998</fpage>–<lpage>125018</lpage>. <pub-id pub-id-type="doi">10.1016/j.talanta.2023.124998</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names> <surname>Brown</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Brill</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Amini</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Nurmi</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name></person-group>, <article-title>Development of better aptamers: structured library approaches, selection methods, and chemical modifications</article-title>, <source>Angew Chem Int Ed</source> <volume>63</volume> (<year>2024</year>) <fpage>e202318665</fpage>. <pub-id pub-id-type="doi">10.1002/anie.202318665</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.R.</given-names> <surname>Bell</surname></string-name>, <string-name><given-names>J.K.</given-names> <surname>Weber</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Yin</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Huynh</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Duan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zhou</surname></string-name></person-group>, <article-title>In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers</article-title>, <source>Proc. Natl. Acad. Sci</source>. <volume>117</volume> (<year>2020</year>) <fpage>8486</fpage>–<lpage>8493</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1913242117</pub-id>.</mixed-citation></ref>
<ref id="c22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.C.</given-names> <surname>Stelzer</surname></string-name>, <string-name><given-names>A.T.</given-names> <surname>Frank</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Kratz</surname></string-name>, <string-name><given-names>M.D.</given-names> <surname>Swanson</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Gonzalez-Hernandez</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Andricioaei</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Markovitz</surname></string-name>, <string-name><given-names>H.M.</given-names> <surname>Al-Hashimi</surname></string-name></person-group>, <article-title>Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble</article-title>, <source>Nat. Chem. Biol</source>. <volume>7</volume> (<year>2011</year>) <fpage>553</fpage>–<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.596</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Niu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Qiao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>K.-Y.</given-names> <surname>Yuen</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Qi</surname></string-name></person-group>, <article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title>, <source>Cell</source> <volume>181</volume> (<year>2020</year>) <fpage>894</fpage>–<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Xia</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhou</surname></string-name></person-group>, <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>, <source>Science</source> <volume>367</volume> (<year>2020</year>) <fpage>1444</fpage>–<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id>.</mixed-citation></ref>
<ref id="c25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Hoffmann</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kleine-Weber</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Schroeder</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Krüger</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Herrler</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Erichsen</surname></string-name>, <string-name><given-names>T.S.</given-names> <surname>Schiergens</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Herrler</surname></string-name>, <string-name><given-names>N.-H.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Nitsche</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Müller</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Drosten</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Pöhlmann</surname></string-name></person-group>, <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>, <source>Cell</source> <volume>181</volume> (<year>2020</year>) <fpage>271</fpage>–<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.</mixed-citation></ref>
<ref id="c26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names> <surname>Ju</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shan</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Tang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Lan</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yuan</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name></person-group>, <article-title>Human neutralizing antibodies elicited by SARS-CoV-2 infection</article-title>, <source>Nature</source> <volume>584</volume> (<year>2020</year>) <fpage>115</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2380-z</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Su</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Bao</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Geng</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Chai</surname></string-name>, <string-name><given-names>R.</given-names> <surname>He</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Lv</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Qiao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Tan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Du</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Xiao</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Su</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Du</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Feng</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Qin</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Qin</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jin</surname></string-name>, <string-name><given-names>X.S.</given-names> <surname>Xie</surname></string-name></person-group>, <article-title>Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells</article-title>, <source>Cell</source> <volume>182</volume> (<year>2020</year>) <fpage>73</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.025</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.D.</given-names> <surname>Boehr</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Nussinov</surname></string-name>, <string-name><given-names>P.E.</given-names> <surname>Wright</surname></string-name></person-group>, <article-title>The role of dynamic conformational ensembles in biomolecular recognition</article-title>, <source>Nat. Chem. Biol</source>. <volume>5</volume> (<year>2009</year>) <fpage>789</fpage>–<lpage>796</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.232</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names> <surname>Qu</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>J.N.</given-names> <surname>Faraone</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Goodarzi</surname></string-name>, <string-name><given-names>Y.-M.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Carlin</surname></string-name>, <string-name><given-names>J.S.</given-names> <surname>Bednash</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Horowitz</surname></string-name>, <string-name><given-names>R.K.</given-names> <surname>Mallampalli</surname></string-name>, <string-name><given-names>L.J.</given-names> <surname>Saif</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Oltz</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Jones</surname></string-name>, <string-name><given-names>R.J.</given-names> <surname>Gumina</surname></string-name>, <string-name><given-names>S.-L.</given-names> <surname>Liu</surname></string-name></person-group>, <article-title>Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and Flip variants</article-title>, <source>Cell</source> <volume>187</volume> (<year>2024</year>) <fpage>585</fpage>–<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.12.026</pub-id>.</mixed-citation></ref>
<ref id="c30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Zuker</surname></string-name></person-group>, <article-title>Mfold web server for nucleic acid folding and hybridization prediction</article-title>, <source>Nucleic Acids Res</source>. <volume>31</volume> (<year>2003</year>) <fpage>3406</fpage>–<lpage>3415</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkg595</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.M.</given-names> <surname>Watkins</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Rangan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Das</surname></string-name></person-group>, <article-title>FARFAR2: improved <italic>de novo</italic> rosetta prediction of complex global RNA folds</article-title>, <source>Structure</source> <volume>28</volume> (<year>2020</year>) <fpage>963</fpage>–<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2020.05.011</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>S.-J.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zhou</surname></string-name></person-group>, <article-title>Modeling Noncanonical RNA Base Pairs by a Coarse-Grained IsRNA2 Model</article-title>, <source>J. Phys. Chem. B</source> <volume>125</volume> (<year>2021</year>) <fpage>11907</fpage>–<lpage>11915</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jpcb.1c07288</pub-id>.</mixed-citation></ref>
<ref id="c33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.J.</given-names> <surname>Boniecki</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Lach</surname></string-name>, <string-name><given-names>W.K.</given-names> <surname>Dawson</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tomala</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Lukasz</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Soltysinski</surname></string-name>, <string-name><given-names>K.M.</given-names> <surname>Rother</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Bujnicki</surname></string-name></person-group>, <article-title>SimRNA: a coarse-grained method for RNA folding simulations and 3D structure prediction</article-title>, <source>Nucleic Acids Res</source>. <volume>44</volume> (<year>2016</year>) <fpage>e63</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1479</pub-id>.</mixed-citation></ref>
<ref id="c34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.A.</given-names> <surname>Tortorici</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Beltramello</surname></string-name>, <string-name><given-names>F.A.</given-names> <surname>Lempp</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Pinto</surname></string-name>, <string-name><given-names>H.V.</given-names> <surname>Dang</surname></string-name>, <string-name><given-names>L.E.</given-names> <surname>Rosen</surname></string-name>, <string-name><given-names>M.</given-names> <surname>McCallum</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bowen</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Minola</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jaconi</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Zatta</surname></string-name>, <string-name><given-names>A.</given-names> <surname>De Marco</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Guarino</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Bianchi</surname></string-name>, <string-name><given-names>E.J.</given-names> <surname>Lauron</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Tucker</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Peter</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Havenar-Daughton</surname></string-name>, <string-name><given-names>J.A.</given-names> <surname>Wojcechowskyj</surname></string-name>, <string-name><given-names>J.B.</given-names> <surname>Case</surname></string-name>, <string-name><given-names>R.E.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Kaiser</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Montiel-Ruiz</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Meury</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Czudnochowski</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Spreafico</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Dillen</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Ng</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Sprugasci</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Culap</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Benigni</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Abdelnabi</surname></string-name>, <string-name><given-names>S.-Y.C.</given-names> <surname>Foo</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Schmid</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Cameroni</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Riva</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Gabrieli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Galli</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Pizzuto</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Neyts</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Diamond</surname></string-name>, <string-name><given-names>H.W.</given-names> <surname>Virgin</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Snell</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Corti</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Fink</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Veesler</surname></string-name></person-group>, <article-title>Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms</article-title>, <source>Science</source> <volume>370</volume> (<year>2020</year>) <fpage>950</fpage>–<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1126/science.abe3354</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Ge</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Ju</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Sun</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Tian</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Shan</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Cheng</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Song</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Ding</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Zhang</surname></string-name></person-group>, <article-title>Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry</article-title>, <source>Nat. Commun</source>. <volume>12</volume> (<year>2021</year>) <fpage>250</fpage>–<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20501-9</pub-id>.</mixed-citation></ref>
<ref id="c36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Gu</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Han</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Hong</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Hong</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Qiao</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Kong</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Qu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Lavillette</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Tang</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Deng</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xie</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Cong</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Huang</surname></string-name></person-group>, <article-title>Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections</article-title>, <source>Nat. Commun</source>. <volume>12</volume> (<year>2021</year>) <fpage>264</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20465-w</pub-id>.</mixed-citation></ref>
<ref id="c37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names> <surname>Ahmed</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Omidian</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Giwa</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Cornwell</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Majety</surname></string-name>, <string-name><given-names>D.R.</given-names> <surname>Bell</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Michels</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Desiderio</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Sadegh-Nasseri</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Rabb</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Gritsch</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Suva</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Cahan</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Jie</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Donner</surname></string-name>, <string-name><given-names>A.R.A.</given-names> <surname>Hamad</surname></string-name></person-group>, <article-title>A public BCR present in a unique dual-receptor-expressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen</article-title>, <source>Cell</source> <volume>177</volume> (<year>2019</year>) <fpage>1583</fpage>–<lpage>1599</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.05.007</pub-id>.</mixed-citation></ref>
<ref id="c38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.C.</given-names> <surname>Nguyen</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Nicolaescu</surname></string-name>, <string-name><given-names>T.J.</given-names> <surname>Best</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Gula</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Saxena</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Gabbard</surname></string-name>, <string-name><given-names>S.-N.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Ohtsuki</surname></string-name>, <string-name><given-names>J.B.</given-names> <surname>Friesen</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Drayman</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Mohamed</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Dann</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Silva</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Robinson-Mailman</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Valdespino</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Stock</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Suárez</surname></string-name>, <string-name><given-names>K.A.</given-names> <surname>Jones</surname></string-name>, <string-name><given-names>S.-A.</given-names> <surname>Azizi</surname></string-name>, <string-name><given-names>J.K.</given-names> <surname>Demarco</surname></string-name>, <string-name><given-names>W.E.</given-names> <surname>Severson</surname></string-name>, <string-name><given-names>C.D.</given-names> <surname>Anderson</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Millis</surname></string-name>, <string-name><given-names>B.C.</given-names> <surname>Dickinson</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tay</surname></string-name>, <string-name><given-names>S.A.</given-names> <surname>Oakes</surname></string-name>, <string-name><given-names>G.F.</given-names> <surname>Pauli</surname></string-name>, <string-name><given-names>K.E.</given-names> <surname>Palmer</surname></string-name></person-group>, <article-title>The National COVID Cohort Collaborative Consortium, D.O. Meltzer, G. Randall, M.R. Rosner, Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses</article-title>, <source>Sci. Adv.</source> <volume>8</volume> (<year>2022</year>) <fpage>eabi6110</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abi6110</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>[39]</label><mixed-citation publication-type="web"><person-group person-group-type="author"><string-name><surname>Emma B</surname>, <given-names>Hodcroft</given-names></string-name></person-group>, “<article-title>CoVariants: SARS-CoV-2 Mutations and Variants of Interest</article-title>.” <ext-link ext-link-type="uri" xlink:href="https://covariants.org/">https://covariants.org/</ext-link>, (<year>2021</year>).</mixed-citation></ref>
<ref id="c40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names> <surname>Sugita</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kitao</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Okamoto</surname></string-name></person-group>, <article-title>Multidimensional replica-exchange method for free-energy calculations</article-title>, <source>J. Chem. Phys</source>. <volume>113</volume> (<year>2000</year>) <fpage>6042</fpage>–<lpage>6051</lpage>. <pub-id pub-id-type="doi">10.1063/1.1308516</pub-id>.</mixed-citation></ref>
<ref id="c41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.J.</given-names> <surname>Woods</surname></string-name>, <string-name><given-names>J.W.</given-names> <surname>Essex</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>King</surname></string-name></person-group>, <article-title>The Development of Replica-Exchange-Based Free-Energy Methods</article-title>, <source>J. Phys. Chem. B</source> <volume>107</volume> (<year>2003</year>) <fpage>13703</fpage>–<lpage>13710</lpage>. <pub-id pub-id-type="doi">10.1021/jp0356620</pub-id>.</mixed-citation></ref>
<ref id="c42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Roux</surname></string-name></person-group>, <article-title>Free Energy Perturbation Hamiltonian Replica-Exchange Molecular Dynamics (FEP/H-REMD) for Absolute Ligand Binding Free Energy Calculations</article-title>, <source>J. Chem. Theory Comput</source>. <volume>6</volume> (<year>2010</year>) <fpage>2559</fpage>–<lpage>2565</lpage>. <pub-id pub-id-type="doi">10.1021/ct1001768</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.H.</given-names> <surname>Ali</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Elsherbiny</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Emara</surname></string-name></person-group>, <article-title>Updates on aptamer research</article-title>, <source>Int. J. Mol. Sci</source>. <volume>20</volume> (<year>2019</year>) <fpage>2511</fpage>–<lpage>2533</lpage>. <pub-id pub-id-type="doi">10.3390/ijms20102511</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Jumper</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pritzel</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Figurnov</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Ronneberger</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tunyasuvunakool</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Bates</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žídek</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Potapenko</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bridgland</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Meyer</surname></string-name>, <string-name><given-names>S.A.A.</given-names> <surname>Kohl</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Ballard</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cowie</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Romera-Paredes</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Nikolov</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Adler</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Back</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Petersen</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Reiman</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Clancy</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zielinski</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Steinegger</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pacholska</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Berghammer</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Bodenstein</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Silver</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Vinyals</surname></string-name>, <string-name><given-names>A.W.</given-names> <surname>Senior</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kavukcuoglu</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kohli</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Hassabis</surname></string-name></person-group>, <article-title>Highly accurate protein structure prediction with AlphaFold</article-title>, <source>Nature</source> <volume>596</volume> (<year>2021</year>) <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>.</mixed-citation></ref>
<ref id="c45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Abramson</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Adler</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Dunger</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Green</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Pritzel</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Ronneberger</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Willmore</surname></string-name>, <string-name><given-names>A.J.</given-names> <surname>Ballard</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bambrick</surname></string-name>, <string-name><given-names>S.W.</given-names> <surname>Bodenstein</surname></string-name>, <string-name><given-names>D.A.</given-names> <surname>Evans</surname></string-name>, <string-name><given-names>C.-C.</given-names> <surname>Hung</surname></string-name>, <string-name><given-names>M.</given-names> <surname>O’Neill</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Reiman</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Tunyasuvunakool</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žemgulytė</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Arvaniti</surname></string-name>, C Beattie, <string-name><given-names>O.</given-names> <surname>Bertolli</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bridgland</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cherepanov</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Congreve</surname></string-name>, <string-name><given-names>A.I.</given-names> <surname>Cowen-Rivers</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cowie</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Figurnov</surname></string-name>, <string-name><given-names>F.B.</given-names> <surname>Fuchs</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Gladman</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Jain</surname></string-name>, <string-name><given-names>Y.A.</given-names> <surname>Khan</surname></string-name>, <string-name><given-names>C.M.R.</given-names> <surname>Low</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Perlin</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Potapenko</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Savy</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Singh</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Stecula</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Thillaisundaram</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Tong</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Yakneen</surname></string-name>, <string-name><given-names>E.D.</given-names> <surname>Zhong</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Zielinski</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Žídek</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Bapst</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kohli</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Jaderberg</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Hassabis</surname></string-name>, <string-name><given-names>J.M.</given-names> <surname>Jumper</surname></string-name></person-group>, <article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title>, <source>Nature</source> <volume>630</volume> (<year>2024</year>) <fpage>493</fpage>–<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-07487-w</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.A.</given-names> <surname>Maier</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Martinez</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kasavajhala</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wickstrom</surname></string-name>, <string-name><given-names>K.E.</given-names> <surname>Hauser</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Simmerling</surname></string-name></person-group>, <article-title>ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title>, <source>J. Chem. Theory Comput</source>. <volume>11</volume> (<year>2015</year>) <fpage>3696</fpage>–<lpage>3713</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names> <surname>Zgarbová</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Šponer</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Otyepka</surname></string-name>, <string-name><given-names>T.E.I.</given-names> <surname>Cheatham</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Galindo-Murillo</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Jurečka</surname></string-name></person-group>, <article-title>Refinement of the sugar–phosphate backbone torsion beta for AMBER force fields improves the description of Z- and B-DNA</article-title>, <source>J. Chem. Theory Comput</source>. <volume>11</volume> (<year>2015</year>) <fpage>5723</fpage>–<lpage>5736</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00716</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zheng</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Jiao</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Wang</surname></string-name></person-group>, <article-title>Post-SELEX optimization of aptamers</article-title>, <source>Anal Bioanal Chem</source>. <volume>408</volume> (<year>2016</year>) <fpage>4567</fpage>–<lpage>4573</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-016-9556-2</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>U.M.</given-names> <surname>Mahajan</surname></string-name>, <string-name><given-names>Q.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Alnatsha</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Maas</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Orth</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Maier</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Peterhansl</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Regel</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Sendler</surname></string-name>, <string-name><given-names>P.R.</given-names> <surname>Wagh</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Mishra</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Xue</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Allawadhi</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Beyer</surname></string-name>, <string-name><given-names>J.-P.</given-names> <surname>Kühn</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Marshall</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Appel</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Lämmerhirt</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Belka</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Müller</surname></string-name>, <string-name><given-names>F.-U.</given-names> <surname>Weiss</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Lauber</surname></string-name>, <string-name><given-names>M.M.</given-names> <surname>Lerch</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Mayerle</surname></string-name></person-group>, <article-title>Tumor-Specific Delivery of 5-Fluorouracil–Incorporated Epidermal Growth Factor Receptor–Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models</article-title>, <source>Gastroenterology</source> <volume>161</volume> (<year>2021</year>) <fpage>996</fpage>–<lpage>1010.e1.</lpage> <pub-id pub-id-type="doi">10.1053/j.gastro.2021.05.055</pub-id>.</mixed-citation></ref>
<ref id="c50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.S.</given-names> <surname>Lee</surname></string-name>, <string-name><given-names>A.K.</given-names> <surname>Wheatley</surname></string-name>, <string-name><given-names>S.J.</given-names> <surname>Kent</surname></string-name>, <string-name><given-names>B.J.</given-names> <surname>DeKosky</surname></string-name></person-group>, <article-title>Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies</article-title>, <source>Nat. Microbiol</source>. <volume>5</volume> (<year>2020</year>) <fpage>1185</fpage>–<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-00789-5</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names> <surname>Krokhotin</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Houlihan</surname></string-name>, <string-name><given-names>N.V.</given-names> <surname>Dokholyan</surname></string-name></person-group>, <article-title>iFoldRNA v2: folding RNA with constraints</article-title>, <source>Bioinformatics</source> <volume>31</volume> (<year>2015</year>) <fpage>2891</fpage>–<lpage>2893</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btv221</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names> <surname>Sarzynska</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Popenda</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Antczak</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Szachniuk</surname></string-name></person-group>, <article-title>RNA tertiary structure prediction using RNAComposer in CASP15</article-title>, <source>Proteins Struct Funct Bioinforma</source>. <volume>91</volume> (<year>2023</year>) <fpage>1790</fpage>–<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1002/prot.26578</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Qiao</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Lei</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Dong</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Tong</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zhou</surname></string-name></person-group>, <article-title>Mutagenesis and structural studies reveal the basis for the specific binding of SARS-CoV-2 SL3 RNA element with human TIA1 protein</article-title>, <source>Nat. Commun</source>. <volume>14</volume> (<year>2023</year>) <fpage>3715</fpage>–<lpage>3726</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-023-39410-8</pub-id>.</mixed-citation></ref>
<ref id="c54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.C.P.</given-names> <surname>van Zundert</surname></string-name>, <string-name><given-names>J.P.G.L.M.</given-names> <surname>Rodrigues</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Trellet</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Schmitz</surname></string-name>, <string-name><given-names>P.L.</given-names> <surname>Kastritis</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Karaca</surname></string-name>, <string-name><given-names>A.S.J.</given-names> <surname>Melquiond</surname></string-name>, <string-name><given-names>M.</given-names> <surname>van Dijk</surname></string-name>, <string-name><given-names>S.J.</given-names> <surname>de Vries</surname></string-name>, <string-name><given-names>A.M.J.J.</given-names> <surname>Bonvin</surname></string-name></person-group>, <article-title>The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes</article-title>, <source>J. Mol. Biol</source>. <volume>428</volume> (<year>2016</year>) <fpage>720</fpage>–<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2015.09.014</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names> <surname>Yan</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>S.-Y.</given-names> <surname>Huang</surname></string-name></person-group>, <article-title>HDOCK: a web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy</article-title>, <source>Nucleic Acids Res</source>. <volume>45</volume> (<year>2017</year>) <fpage>W365</fpage>–<lpage>W373</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx407</pub-id>.</mixed-citation></ref>
<ref id="c56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.G.</given-names> <surname>Pierce</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Wiehe</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Hwang</surname></string-name>, <string-name><given-names>B.-H.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Vreven</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Weng</surname></string-name></person-group>, <article-title>ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers</article-title>, <source>Bioinformatics</source> <volume>30</volume> (<year>2014</year>) <fpage>1771</fpage>–<lpage>1773</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btu097</pub-id>.</mixed-citation></ref>
<ref id="c57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names> <surname>Lyskov</surname></string-name>, <string-name><given-names>F.-C.</given-names> <surname>Chou</surname></string-name>, <string-name><given-names>S.Ó.</given-names> <surname>Conchúir</surname></string-name>, <string-name><given-names>B.S.</given-names> <surname>Der</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Drew</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Kuroda</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>B.D.</given-names> <surname>Weitzner</surname></string-name>, <string-name><given-names>P.D.</given-names> <surname>Renfrew</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Sripakdeevong</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Borgo</surname></string-name>, <string-name><given-names>J.J.</given-names> <surname>Havranek</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Kuhlman</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kortemme</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Bonneau</surname></string-name>, <string-name><given-names>J.J.</given-names> <surname>Gray</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Das</surname></string-name></person-group>, <article-title>Serverification of Molecular Modeling Applications: The Rosetta Online Server That Includes Everyone (ROSIE)</article-title>, <source>PLOS One</source> <volume>8</volume> (<year>2013</year>) <fpage>e63906</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0063906</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names> <surname>Páll</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Zhmurov</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Bauer</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Abraham</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Lundborg</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Gray</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Hess</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Lindahl</surname></string-name></person-group>, <article-title>Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS</article-title>, <source>J. Chem. Phys</source>. <volume>153</volume> (<year>2020</year>) <fpage>134110</fpage>–<lpage>134124</lpage>. <pub-id pub-id-type="doi">10.1063/5.0018516</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.L.</given-names> <surname>Jorgensen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Chandrasekhar</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Madura</surname></string-name>, <string-name><given-names>R.W.</given-names> <surname>Impey</surname></string-name>, <string-name><given-names>M.L.</given-names> <surname>Klein</surname></string-name></person-group>, <article-title>Comparison of simple potential functions for simulating liquid water</article-title>, <source>J. Chem. Phys</source>. <volume>79</volume> (<year>1983</year>) <fpage>926</fpage>–<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1063/1.445869</pub-id>.</mixed-citation></ref>
    <ref id="c60"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>L.F.</given-names> <surname>Song</surname></string-name> <string-name><surname>Merz</surname><given-names>K.M.</given-names><suffix>Jr</suffix></string-name></person-group> <article-title>Systematic parameterization of monovalent ions employing the nonbonded model</article-title>, <source>J. Chem. Theory Comput</source>. <volume>11</volume> (<year>2015</year>) <fpage>1645</fpage>–<lpage>1657</lpage>. <pub-id pub-id-type="doi">10.1021/ct500918t</pub-id>.</mixed-citation></ref>
<ref id="c61"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.S.</given-names> <surname>Valdés-Tresanco</surname></string-name>, <string-name><given-names>M.E.</given-names> <surname>Valdés-Tresanco</surname></string-name>, <string-name><given-names>P.A.</given-names> <surname>Valiente</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Moreno</surname></string-name></person-group>, <article-title>gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS</article-title>, <source>J. Chem. Theory Comput</source>. <volume>17</volume> (<year>2021</year>) <fpage>6281</fpage>–<lpage>6291</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.1c00645</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107785.2.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Frank</surname>
<given-names>Aaron</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/049d04r12</institution-id><institution>Arrakis Therapeutics</institution>
</institution-wrap>
<city>Waltham</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>valuable</bold> study introduces CAAMO, a computational framework that combines structure prediction, in silico mutagenesis, molecular simulations, and energy calculations to design RNA aptamers with improved binding affinity. The computational methodology is <bold>solid</bold>, demonstrating strong theoretical foundations and systematic integration of multiple prediction techniques. However, the experimental validation is <bold>incomplete</bold>, with methodological weaknesses that limit the strength of support for the computational predictions.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107785.2.sa1</article-id>
<title-group>
<article-title>Reviewer #4 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The authors demonstrate a computational rational design approach for developing RNA aptamers with improved binding to the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein. They demonstrate the ability of their approach to improve binding affinity using a previously identified RNA aptamer, RBD-PB6-Ta, which binds to the RBD. They also computationally estimate the binding energies of various RNA aptamers with the RBD and compare against RBD binding energies for a few neutralizing antibodies from the literature. Finally, experimental binding affinities are estimated by electrophoretic mobility shift assays (EMSA) for various RNA aptamers and a single commercially available neutralizing antibody to support the conclusions from computational studies on binding. The authors conclude that their computational framework, CAAMO, can provide reliable structure predictions and effectively support rational design of improved affinity for RNA aptamers towards target proteins. Additionally, they claim that their approach achieved design of high affinity RNA aptamer variants that bind to the RBD as well or better than a commercially available neutralizing antibody.</p>
<p>Strengths:</p>
<p>The thorough computational approaches employed in the study provide solid evidence of the value of their approach for computational design of high affinity RNA aptamers. The theoretical analysis using Free Energy Perturbation (FEP) to estimate relative binding energies supports the claimed improvement of affinity for RNA aptamers and provides valuable insight into the binding model for the tested RNA aptamers in comparison to previously studied neutralizing antibodies. The multimodal structure prediction in the early stages of the presented CAAMO framework, combined with the demonstrated outcome of improved affinity using the structural predictions as a starting point for rational design, provide moderate confidence in the structure predictions.</p>
<p>Weaknesses:</p>
<p>The experimental characterization of RBD affinities for the antibody and RNA aptamers in this study present serious concerns regarding the methods used and the data presented in the manuscript, which call into question the major conclusions regarding affinity towards the RBD for their aptamers compared to antibodies. The claim that structural predictions from CAAMO are reasonable is rational, but this claim would be significantly strengthened by experimental validation of the structure (i.e. by chemical footprinting or solving the RBD-aptamer complex structure).</p>
<p>The conclusions in this work are somewhat supported by the data, but there are significant issues with experimental methods that limit the strength of the study's conclusions.</p>
<p>(1) The EMSA experiments have a number of flaws that limit their interpretability. The uncropped electrophoresis images, which should include molecular size markers and/or positive and negative controls for bound and unbound complex components to support interpretation of mobility shifts, are not presented. In fact, a spliced image can be seen for Figure 4E, which limits interpretation without the full uncropped image. Additionally, he volumes of EMSA mixtures are not presented when a mass is stated (i.e. for the methods used to create Figure 3D), which leaves the reader without the critical parameter, molar concentration, and therefore leaves in question the claim that the tested antibody is high affinity under the tested conditions. Additionally, protein should be visualized in all gels as a control to ensure that lack of shifts is not due to absence/aggregation/degradation of the RBD protein. In the case of Figure 3E, for example, it can be seen that there are degradation products included in the RBD-only lane, introducing a reasonable doubt that the lack of a shift in RNA tests (i.e. Figure 2F) is conclusively due to a lack of binding. Finally, there is no control for nonspecific binding, such as BSA or another non-target protein, which fails to eliminate the possibility of nonspecific interactions between their designed aptamers and proteins in general. A nonspecific binding control should be included in all EMSA experiments.</p>
<p>(2) The evidence supporting claims of better binding to RBD by the aptamer compared to the commercial antibody is flawed at best. The commercial antibody product page indicates an affinity in low nanomolar range, whereas the fitted values they found for the aptamers in their study are orders of magnitude higher at tens of micromolar. Moreover, the methods section is lacking in the details required to appropriately interpret the competitive binding experiments. With a relatively short 20-minute equilibration time, the order of when the aptamer is added versus the antibody makes a difference in which is apparently bound. The issue with this becomes apparent with the lack of internal consistency in the presented results, namely in comparing Fig 3E (which shows no interference of Ta binding with 5uM antibody) and Fig 5D (which shows interference of Ta binding with 0.67-1.67uM antibody). The discrepancy between these figures calls into question the methods used, and it necessitates more details regarding experimental methods used in this manuscript.</p>
<p>(3) The utility of the approach for increasing affinity of RNA aptamers for their targets is well supported through computational and experimental techniques demonstrating relative improvements in binding affinity for their G34C variant compared to the starting Ta aptamer. While the EMSA experiments do have significant flaws, the observations of relative relationships in equilibrium binding affinities among the tested aptamer variants can be interpreted with reasonable confidence, given that they were all performed in a consistent manner.</p>
<p>(4) The claim that the structure of the RBD-Aptamer complex predicted by the CAAMO pipeline is reliable is tenuous. The success of their rational design approach based on the structure predicted by several ensemble approaches supports the interpretation of the predicted structure as reasonable, however, no experimental validation is undertaken to assess the accuracy of the structure. This is not a main focus of the manuscript, given the applied nature of the study to identify Ta variants with improved binding affinity, however the structural accuracy claim is not strongly supported without experimental validation (i.e. chemical footprinting methods).</p>
<p>(5) Throughout the manuscript, the phrasing of &quot;all tested antibodies&quot; was used, despite there being only one tested antibody in experimental methods and three distinct antibodies in computational methods. While this concern is focused on specific language, the major conclusion that their designed aptamers are as good or better than neutralizing antibodies in general is weakened by only testing only three antibodies through computational binding measurements and a fourth single antibody for experimental testing. The contact residue mapping furthermore lacks clarity in the number of structures that were used, with a vague description of structures from the PDB including no accession numbers provided nor how many distinct antibodies were included for contact residue mapping.</p>
<p>Overall, the manuscript by Yang et al presents a valuable tool for rational design of improved RNA aptamer binding affinity toward target proteins, which the authors call CAAMO. Notably, the method is not intended for de novo design, but rather as a tool for improving aptamers that have been selected for binding affinity by other methods such as SELEX. While there are significant issues in the conclusions made from experiments in this manuscript, the relative relationships of observed affinities within this study provide solid evidence that the CAAMO framework provides a valuable tool for researchers seeking to use rational design approaches for RNA aptamer affinity maturation.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.107785.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Yanqing</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiao</surname>
<given-names>Lulu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yangwei</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Zhiye</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Dong</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7297-5083</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Buratto</surname>
<given-names>Damiano</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9924-128X</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Liquan</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3400-0685</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Ruhong</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8624-5591</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the current reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #4 (Public review):</bold></p>
<p>Summary:</p>
<p>The authors demonstrate a computational rational design approach for developing RNA aptamers with improved binding to the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein. They demonstrate the ability of their approach to improve binding affinity using a previously identified RNA aptamer, RBD-PB6-Ta, which binds to the RBD. They also computationally estimate the binding energies of various RNA aptamers with the RBD and compare against RBD binding energies for a few neutralizing antibodies from the literature. Finally, experimental binding affinities are estimated by electrophoretic mobility shift assays (EMSA) for various RNA aptamers and a single commercially available neutralizing antibody to support the conclusions from computational studies on binding. The authors conclude that their computational framework, CAAMO, can provide reliable structure predictions and effectively support rational design of improved affinity for RNA aptamers towards target proteins. Additionally, they claim that their approach achieved design of high affinity RNA aptamer variants that bind to the RBD as well or better than a commercially available neutralizing antibody.</p>
<p>Strengths:</p>
<p>The thorough computational approaches employed in the study provide solid evidence of the value of their approach for computational design of high affinity RNA aptamers. The theoretical analysis using Free Energy Perturbation (FEP) to estimate relative binding energies supports the claimed improvement of affinity for RNA aptamers and provides valuable insight into the binding model for the tested RNA aptamers in comparison to previously studied neutralizing antibodies. The multimodal structure prediction in the early stages of the presented CAAMO framework, combined with the demonstrated outcome of improved affinity using the structural predictions as a starting point for rational design, provide moderate confidence in the structure predictions.</p>
</disp-quote>
<p>We thank the reviewer for this accurate summary and for recognizing the strength of our integrated computational–experimental workflow in improving aptamer affinity.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>The experimental characterization of RBD affinities for the antibody and RNA aptamers in this study present serious concerns regarding the methods used and the data presented in the manuscript, which call into question the major conclusions regarding affinity towards the RBD for their aptamers compared to antibodies. The claim that structural predictions from CAAMO are reasonable is rational, but this claim would be significantly strengthened by experimental validation of the structure (i.e. by chemical footprinting or solving the RBD-aptamer complex structure).</p>
<p>The conclusions in this work are somewhat supported by the data, but there are significant issues with experimental methods that limit the strength of the study's conclusions.</p>
<p>(1) The EMSA experiments have a number of flaws that limit their interpretability. The uncropped electrophoresis images, which should include molecular size markers and/or positive and negative controls for bound and unbound complex components to support interpretation of mobility shifts, are not presented. In fact, a spliced image can be seen for Figure 4E, which limits interpretation without the full uncropped image.</p>
</disp-quote>
<p>Thank you for your valuable comments and careful review.</p>
<p>In response to your suggestion, we will provide all uncropped electrophoresis raw images corresponding to the results in the main figures and supplementary figures (Figure 2F, 3D, 3E, 4E, S9A and S10 of the original manuscript) in the revised version. Regarding the spliced image in Figure 4E, the uncropped raw gel image clearly shows that the two C23U samples were run on an adjacent lane of the same gel due to the total number of samples exceeding the well capacity of a single lane. All samples were electrophoresed and signal-detected under identical experimental conditions in one single experiment, ensuring the validity of direct signal intensity comparison across all samples. These complete uncropped raw images will be supplemented in the revised manuscript as Figure S12 (also see Author response image 1).</p>
<fig id="sa2fig1">
<label>Author response image 1.</label>
<caption>
<title>Uncropped electrophoresis images corresponding to Figures 2F, 3D, 3E, 4E, S9A and S10 of the original manuscript.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-107785-sa2-fig1.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>Additionally, he volumes of EMSA mixtures are not presented when a mass is stated (i.e. for the methods used to create Figure 3D), which leaves the reader without the critical parameter, molar concentration, and therefore leaves in question the claim that the tested antibody is high affinity under the tested conditions.</p>
</disp-quote>
<p>Thank you for your valuable comment on this oversight.</p>
<p>For the EMSA assay in Figure 3D, the reaction mixture (10 μL total volume) contained 3 μg of RBD protein and 3 μg of antibody (40592-R001), either individually or in combination, with incubation at room temperature for 20 minutes. Based on the molecular weights (35 kDa for RBD and 150 kDa for the IgG antibody), the corresponding molar concentrations in the mixture were calculated as 8.57 μM for RBD and 2 μM for the antibody. To ensure consistency, clarity and provide the critical molar concentration parameter, we will revise the legend of Figure 3D, replacing the mass values with the calculated molar concentrations as you suggested in the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>Additionally, protein should be visualized in all gels as a control to ensure that lack of shifts is not due to absence/aggregation/degradation of the RBD protein. In the case of Figure 3E, for example, it can be seen that there are degradation products included in the RBD-only lane, introducing a reasonable doubt that the lack of a shift in RNA tests (i.e. Figure 2F) is conclusively due to a lack of binding.</p>
</disp-quote>
<p>We sincerely appreciate your careful evaluation of our work, which helps us further clarify the experimental details and data reliability.</p>
<p>First, we would like to clarify the nature of the gel electrophoresis in Figure 3E: the RBD protein was separated by native-PAGE rather than denaturing SDS-PAGE. The RBD protein used in all experiments was purchased from HUABIO (Cat. No. HA210064) with guaranteed quality, and its integrity and purity were independently verified in our laboratory via denaturing SDS-PAGE (see Author response image 2), which showed a single, intact band without any degradation products. The ladder-like bands observed in the RBD-only lane of the native-PAGE gel are not a result of protein degradation. Instead, they arise from two well-characterized properties of recombinant SARS-CoV-2 Spike RBD protein expressed in human cells: intrinsic conformational heterogeneity (the RBD domain exists in multiple dynamic conformations due to its structural flexibility) (Cai et al., Science, 2020; Wrapp et al., Science, 2020) and heterogeneity in N-glycosylation modification (variable glycosylation patterns at the conserved N-glycosylation sites of RBD) (Casalino et al., ACS Cent. Sci., 2020; Ives et al., eLife, 2024), both of which could cause distinct migration bands in native-PAGE under non-denaturing conditions.</p>
<p>Second, to ensure the reliability of the RNA-binding results, the EMSA experiments for determining the binding affinity (K<sub>d</sub>) of RBD to Ta, Tc and Ta variants were performed with three independent biological replicates (the original manuscript includes all replicate data in Figure 2F and S9). Consistent results were obtained across all replicates, which effectively rules out false-negative outcomes caused by accidental absence or loss of functional RBD protein in the reaction system. In addition, our gel images (Figure 2F and S9 in the original manuscript) and uncropped raw images of all EMSA gels (see Author response image 1) show no significant signal accumulation in the sample wells, confirming the absence of RBD protein aggregation in the binding reactions—an issue that would otherwise interfere with RNA-protein interaction and band shift detection.</p>
<p>New results for RBD analysis by denaturing SDS-PAGE, along with the associated discussion, will be added to the revised manuscript as Figure S10 (also see Author response image 2).</p>
<fig id="sa2fig2">
<label>Author response image 2.</label>
<caption>
<title>SDS-PAGE analysis of the SARS-CoV-2 Spike RBD protein, neutralizing antibody (40592-R001) and BSA reference.</title>
<p>This gel validates the high purity and structural integrity of the commercially sourced RBD protein and neutralizing antibody used in this study.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-107785-sa2-fig2.jpg" mimetype="image"/>
</fig>
<p>References</p>
<p>Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike proteins. Science 369, 1586-1592 (2020).</p>
<p>Casalino, L. et al. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. ACS Cent. Sci. 6, 1722-1734 (2020).</p>
<p>Ives, C.M. et al. Role of N343 glycosylation on the SARS-CoV-2 S RBD structure and co-receptor binding across variants of concern. eLife 13, RP95708 (2024).</p>
<p>Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263 (2020).</p>
<disp-quote content-type="editor-comment">
<p>Finally, there is no control for nonspecific binding, such as BSA or another non-target protein, which fails to eliminate the possibility of nonspecific interactions between their designed aptamers and proteins in general. A nonspecific binding control should be included in all EMSA experiments.</p>
</disp-quote>
<p>Thank you for this constructive comment.</p>
<p>Following your recommendation, we are currently supplementing the EMSA assays with BSA as a non-target protein control to rigorously exclude potential non-specific binding between our designed aptamers (Ta and Ta variants) and exogenous proteins. These additional experiments are designed to directly assess whether the aptamers exhibit unintended interactions with unrelated proteins and to further validate the protein specificity of the RBD–aptamer interaction observed in our study.</p>
<p>The resulting nonspecific binding control data will be formally incorporated into the revised manuscript as Figure S11, and the corresponding Results and Discussion sections will be updated accordingly to reflect this critical validation once the experiments are completed.</p>
<disp-quote content-type="editor-comment">
<p>(2) The evidence supporting claims of better binding to RBD by the aptamer compared to the commercial antibody is flawed at best. The commercial antibody product page indicates an affinity in low nanomolar range, whereas the fitted values they found for the aptamers in their study are orders of magnitude higher at tens of micromolar. Moreover, the methods section is lacking in the details required to appropriately interpret the competitive binding experiments. With a relatively short 20-minute equilibration time, the order of when the aptamer is added versus the antibody makes a difference in which is apparently bound. The issue with this becomes apparent with the lack of internal consistency in the presented results, namely in comparing Fig 3E (which shows no interference of Ta binding with 5uM antibody) and Fig 5D (which shows interference of Ta binding with 0.67-1.67uM antibody). The discrepancy between these figures calls into question the methods used, and it necessitates more details regarding experimental methods used in this manuscript.</p>
</disp-quote>
<p>Thank you for your insightful comments, which have helped us refine the rigor of our study. We address each of your concerns in detail below:</p>
<p>First, we agree with your observation that the commercial neutralizing antibody (Sino Biological, Cat# 40592-R001) is reported to bind Spike RBD with low nanomolar affinity on its product page. However, this discrepancy in affinity values (nanomolar vs. micromolar) stems from the use of distinct analytical methods. The product page affinity was determined via the Octet RED System, a technique analogous to Surface Plasmon Resonance (SPR) that offers high sensitivity for kinetic and affinity measurements. In contrast, our study employed EMSA, a method primarily optimized for semi-quantitative assessment of binding interactions. The inherent differences in sensitivity and principle between these two techniques—with Octet RED System enabling real-time monitoring of biomolecular interactions and EMSA relying on gel separation—account for the observed variation in affinity values.</p>
<p>Second, regarding the competitive binding experiments, we appreciate your note on the critical role of reagent addition order and equilibration time. To eliminate potential biases from sequential addition, we clarify that Cy3-labeled RNAs, RBD proteins, and the neutralizing antibody were added simultaneously to the reaction system. We will revise the Methods section in the revised manuscript to provide a detailed protocol for the EMSA experiments, to ensure full reproducibility and appropriate interpretation of the results.</p>
<p>Third, we acknowledge and apologize for a critical error in the figure legends of Figure 3E: the concentrations reported (5 μM aptamer and antibody 40592-R001) refer to stock solutions, not the final concentrations in the EMSA reaction mixture. The correct final concentrations are 0.5 μM for aptamer Ta, and 0.5 μM for the antibody. This correction resolves the apparent inconsistency between Figure 3E and Figure 5D, as the final antibody concentration in Figure 3E is now consistent with the concentration range used in Figure 5D. We will update the figure legends for Figure 3E and revise the Methods section to explicitly distinguish between stock and final reaction concentrations, ensuring clarity and internal consistency of the results.</p>
<p>We sincerely thank you for highlighting these issues, which will prompt important revisions to improve the clarity, accuracy, and rigor of our manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(3) The utility of the approach for increasing affinity of RNA aptamers for their targets is well supported through computational and experimental techniques demonstrating relative improvements in binding affinity for their G34C variant compared to the starting Ta aptamer. While the EMSA experiments do have significant flaws, the observations of relative relationships in equilibrium binding affinities among the tested aptamer variants can be interpreted with reasonable confidence, given that they were all performed in a consistent manner.</p>
</disp-quote>
<p>We sincerely appreciate your valuable concerns and constructive feedback, which have greatly facilitated the improvement of our manuscript. Regarding the flaws of the EMSA experiments you pointed out, we have provided a detailed response to clarify the related issues and supplemented necessary experimental details to enhance the rigor and reproducibility of our work (see corresponding response above). It is worth noting that EMSA remains a classic and widely used technique for studying biomolecular interactions, and its reliability in qualitative and semi-quantitative analysis of binding events has been well recognized in the field. Furthermore, we fully agree with and are grateful for your view that, since all tested aptamer variants were analyzed using a consistent experimental protocol, the observations on the relative relationships of their equilibrium binding affinities can be interpreted with reasonable confidence. This recognition reinforces the validity of the relative affinity improvements we observed for the G34C variant compared to the parental Ta aptamer, which is a key finding of our study.</p>
<disp-quote content-type="editor-comment">
<p>(4) The claim that the structure of the RBD-Aptamer complex predicted by the CAAMO pipeline is reliable is tenuous. The success of their rational design approach based on the structure predicted by several ensemble approaches supports the interpretation of the predicted structure as reasonable, however, no experimental validation is undertaken to assess the accuracy of the structure. This is not a main focus of the manuscript, given the applied nature of the study to identify Ta variants with improved binding affinity, however the structural accuracy claim is not strongly supported without experimental validation (i.e. chemical footprinting methods).</p>
</disp-quote>
<p>We thank the reviewer for this comment and agree that experimental validation would be required to establish the structural accuracy of the predicted RBD–aptamer complex. We note, however, that the primary aim of this study is not structural determination, but the development of a general computational framework for aptamer affinity maturation. In most practical applications, experimentally resolved structures of aptamer–protein complexes are unavailable. Accordingly, CAAMO is designed to operate under such conditions, using computationally generated binding models as working hypotheses to guide rational optimization rather than as definitive structural descriptions. In this context, the predicted structure is evaluated by its utility for affinity improvement, rather than by direct structural validation. We will revise the manuscript accordingly to further clarify this scope.</p>
<disp-quote content-type="editor-comment">
<p>(5) Throughout the manuscript, the phrasing of &quot;all tested antibodies&quot; was used, despite there being only one tested antibody in experimental methods and three distinct antibodies in computational methods. While this concern is focused on specific language, the major conclusion that their designed aptamers are as good or better than neutralizing antibodies in general is weakened by only testing only three antibodies through computational binding measurements and a fourth single antibody for experimental testing. The contact residue mapping furthermore lacks clarity in the number of structures that were used, with a vague description of structures from the PDB including no accession numbers provided nor how many distinct antibodies were included for contact residue mapping.</p>
</disp-quote>
<p>We thank the reviewer for this important comment regarding language precision, experimental scope, and clarity of the antibody dataset used in this study. We agree that the phrase “all tested antibodies” was imprecise and could lead to overgeneralization. We will carefully revise the manuscript to use more accurate and explicit wording throughout, clearly distinguishing between experimentally tested antibodies, computationally analyzed antibodies, and antibody structures used for large-scale contact analysis.</p>
<p>Specifically, the experimental comparison in this study was performed using one commercially available SARS-CoV-2 neutralizing antibody, whereas free energy–based computational analyses were conducted on three representative neutralizing antibodies with available structural data. We will revise the manuscript to explicitly state these distinctions and avoid general statements referring to neutralizing antibodies as a class.</p>
<p>Importantly, the residue-level contact frequency analysis was not based solely on these individual antibodies. Instead, this analysis leveraged a comprehensive set of experimentally resolved SARS-CoV-2 RBD–antibody complex structures curated from the Coronavirus Antibody Database (CoV-AbDab), a publicly available and actively maintained resource developed by the Oxford Protein Informatics Group. CoV-AbDab aggregates all published coronavirus-binding antibodies with associated PDB structures and provides a systematic and unbiased structural foundation for antibody–RBD interaction analysis. All available high-resolution RBD–antibody complex structures indexed in CoV-AbDab at the time of analysis were included to compute contact residue frequencies across the structural ensemble. We will explicitly state this data source, clarify the number and nature of structures used, and add the appropriate citation (Raybould et al., Bioinformatics, 2021, doi: 10.1093/bioinformatics/btaa739).</p>
<p>Finally, we will revise the conclusions to avoid claims that extend beyond the scope of the data. The comparison between aptamers and antibodies is now framed in terms of representative antibodies and consensus interaction patterns derived from a large structural ensemble, rather than as a general statement about all neutralizing antibodies. These revisions will improve the clarity, rigor, and reproducibility of the manuscript, while preserving the core conclusion that the CAAMO framework enables effective structure-guided affinity maturation of RNA aptamers.</p>
<disp-quote content-type="editor-comment">
<p>Overall, the manuscript by Yang et al presents a valuable tool for rational design of improved RNA aptamer binding affinity toward target proteins, which the authors call CAAMO. Notably, the method is not intended for de novo design, but rather as a tool for improving aptamers that have been selected for binding affinity by other methods such as SELEX. While there are significant issues in the conclusions made from experiments in this manuscript, the relative relationships of observed affinities within this study provide solid evidence that the CAAMO framework provides a valuable tool for researchers seeking to use rational design approaches for RNA aptamer affinity maturation.</p>
</disp-quote>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>Summary:</p>
<p>In this study, the authors attempt to devise general rules for aptamer design based on structure and sequence features. The main system they are testing is an aptamer targeting a viral sequence.</p>
<p>Strengths:</p>
<p>The method combines a series of well-established protocols, including docking, MD, and a lot of system-specific knowledge, to design several new versions of the Ta aptamer with improved binding affinity.</p>
</disp-quote>
<p>We thank the reviewer for this accurate summary and for recognizing the strength of our integrated computational–experimental workflow in improving aptamer affinity.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>The approach requires a lot of existing knowledge and, importantly, an already known aptamer, which presumably was found with SELEX. In addition, although the aptamer may have a stronger binding affinity, it is not clear if any of it has any additional useful properties such as stability, etc.</p>
</disp-quote>
<p>Thanks for these critical comments.</p>
<p>(1) On the reliance on a known aptamer: We agree that our CAAMO framework is designed as a post-SELEX optimization platform rather than a tool for <italic>de novo</italic> discovery. Its primary utility lies in rationally enhancing the affinity of existing aptamers that may not yet be sequence-optimal, thereby complementing experimental technologies such as SELEX. The following has been added to “Introduction” of the revised manuscript. (Page 5, line 108 in the revised manuscript)</p>
<p>‘Rather than serving as a de novo aptamer discovery tool, CAAMO is designed as a post-SELEX optimization platform that rationally improves the binding capability of existing aptamers.’</p>
<p>(2) On stability and developability: We also appreciate the reviewer’s important reminder that affinity alone is not sufficient for therapeutic development. We acknowledge that the present study has focused mainly on affinity optimization, and properties such as nuclease resistance, structural stability, and overall developability were not evaluated. The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 25, line 595 in the revised manuscript)</p>
<p>‘While the present study primarily focused on affinity optimization, we acknowledge that other key developability traits—such as nuclease resistance, structural and thermodynamic stability, and in vivo persistence—are equally critical for advancing aptamers toward therapeutic applications. These properties were not evaluated here but will be systematically addressed in future iterations of the CAAMO framework to enable comprehensive optimization of aptamer candidates.’</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>Summary:</p>
<p>This manuscript proposes a workflow for discovering and optimizing RNA aptamers, with application in the optimization of a SARS-CoV-2 RBD. The authors took a previously identified RNA aptamer, computationally docked it into one specific RBD structure, and searched for variants with higher predicted affinity. The variants were subsequently tested for RBD binding using gel retardation assays and competition with antibodies, and one was found to be a stronger binder by about three-fold than the founding aptamer.</p>
<p>Overall, this would be an interesting study if it were performed with truly high-affinity aptamers, and specificity was shown for RBD or several RBD variants.</p>
<p>Strengths:</p>
<p>The computational workflow appears to mostly correctly find stronger binders, though not de novo binders.</p>
</disp-quote>
<p>We thank the reviewer for the clear summary and for acknowledging that our workflow effectively prioritizes stronger binders.</p>
<disp-quote content-type="editor-comment">
<p>Weaknesses:</p>
<p>(1) Antibody competition assays are reported with RBD at 40 µM, aptamer at 5 µM, and a titration of antibody between 0 and 1.2 µg. This approach does not make sense. The antibody concentration should be reported in µM. An estimation of the concentration is 0-8 pmol (from 0-1.2 µg), but that's not a concentration, so it is unknown whether enough antibody molecules were present to saturate all RBD molecules, let alone whether they could have displaced all aptamers.</p>
</disp-quote>
<p>Thanks for your insightful comment. We have calculated that 0–1.2 µg antibody corresponds to a final concentration range of 0–1.6 µM (see Author response image 1). In practice, 1.2 µg was the maximum amount of commercial antibody that could be added under the conditions of our assay. In the revised manuscript, all antibody amounts previously reported in µg have been converted to their corresponding molar concentrations in Fig. 1F and Fig. 5D. In addition, the exact antibody concentrations used in the EMSA assays are now explicitly stated in the Materials and Methods section under “EMSA experiments.” The following has been added to “EMSA experiments” of the revised manuscript. (Page 30 in the revised manuscript)</p>
<p>‘For competitive binding experiments, 40 μM of RBP proteins, 5 μM of annealed Cy3-labelled RNAs and increasing concentrations of SARS-CoV-2 neutralizing antibody 40592-R001 (0–1.67 μM) were mixed in the EMSA buffer and incubated at room temperature for 20 min.’</p>
<fig id="sa2fig3">
<label>Author response image 1.</label>
<caption>
<title>Estimation of antibody concentration.</title>
<p>Assuming a molecular weight of 150 kDa, dissolving 1.2 µg of antibody in a 5 µL reaction volume results in a final concentration of 1.6 µM.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-107785-sa2-fig3.jpg" mimetype="image"/>
</fig>
<p>As shown in Figure 5D, the purpose of the antibody–aptamer competition assay was not to achieve full saturation but rather to compare the relative competitive binding of the optimized aptamer (Ta<sup>G34C</sup>) versus the parental aptamer (Ta). Molecular interactions at this scale represent a dynamic equilibrium of binding and dissociation. While the antibody concentration may not have been sufficient to saturate all available RBD molecules, the experimental results clearly reveal the competitive binding behavior that distinguishes the two aptamers. Specifically, two consistent trends emerged:</p>
<p>(1) Across all antibody concentrations, the free RNA band for Ta was stronger than that of Ta<sup>G34C</sup>, while the RBD–RNA complex band of the latter was significantly stronger, indicating that Ta<sup>G34C</sup> bound more strongly to RBD.</p>
<p>(2) For Ta, increasing antibody concentration progressively reduced the RBD–RNA complex band, consistent with antibody displacing the aptamer. In contrast, for Ta<sup>G34C</sup>, the RBD–RNA complex band remained largely unchanged across all tested antibody concentrations, suggesting that the antibody was insufficient to displace Ta<sup>G34C</sup> from the complex.</p>
<p>Together, these observations support the conclusion that Ta<sup>G34C</sup> exhibits markedly stronger binding to RBD than the parental Ta aptamer, in line with the predictions and objectives of our CAAMO optimization framework.</p>
<disp-quote content-type="editor-comment">
<p>(2) These are not by any means high-affinity aptamers. The starting sequence has an estimated (not measured, since the titration is incomplete) <italic>K<sub>d</sub></italic> of 110 µM. That's really the same as non-specific binding for an interaction between an RNA and a protein. This makes the title of the manuscript misleading. No high-affinity aptamer is presented in this study. If the docking truly presented a bound conformation of an aptamer to a protein, a sub-micromolar <italic>K<sub>d</sub></italic> would be expected, based on the number of interactions that they make.</p>
</disp-quote>
<p>In fact, our starting sequence (Ta) is a high-affinity aptamer, and then the optimized sequences (such as Ta<sup>G34C</sup>) with enhanced affinity are undoubtedly also high-affinity aptamers. See descriptions below:</p>
<p>(1) Origin and prior characterization of Ta. The starting aptamer Ta (referred to as RBD-PB6-Ta in the original publication by Valero et al., PNAS 2021, doi:10.1073/pnas.2112942118) was selected through multiple positive rounds of SELEX against SARS-CoV-2 RBD, together with counter-selection steps to eliminate non-specific binders. In that study, Ta was reported to bind RBD with an IC₅₀ of ~200 nM as measured by biolayer interferometry (BLI), supporting its high affinity and specificity. The following has been added to “Introduction” of the revised manuscript. (Page 4 in the revised manuscript)</p>
<p>‘This aptamer was originally identified through SELEX and subsequently validated using surface plasmon resonance (SPR) and biolayer interferometry (BLI), which confirmed its high affinity (sub-nanomolar) and high specificity toward the RBD. Therefore, Ta provides a well-characterized and biologically relevant starting point for structure-based optimization.’</p>
<p>(2) Methodological differences between EMSA and BLI measurements. We acknowledge that the discrepancy between our obtained binding affinity (<italic>K<sub>d</sub></italic> = 110 µM) and the previously reported one (<italic>IC<sub>50</sub></italic> ~ 200 nM) for the same Ta sequence arises primarily from methodological and experimental differences between EMSA and BLI. Namely, different experimental measurement methods can yield varied binding affinity values. While EMSA may have relatively low measurement precision, its relatively simple procedures were the primary reason for its selection in this study. Particularly, our framework (CAAMO) is designed not as a tool for absolute affinity determination, but as a post-SELEX optimization platform that prioritizes relative changes in binding affinity under a consistent experimental setup. Thus, the central aim of our work is to demonstrate that CAAMO can reliably identify variants, such as Ta<sup>G34C</sup>, that bind more strongly than the parental sequence under identical assay conditions. The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 24 in the revised manuscript)</p>
<p>‘Although the absolute <italic>K<sub>d</sub></italic> values determined by EMSA cannot be directly compared with surface-based methods such as SPR or BLI, the relative affinity trends remain highly consistent. While EMSA provides semi-quantitative affinity estimates, the close agreement between experimental EMSA trends and FEP-calculated ΔΔG values supports the robustness of the relative affinity changes reported here. In future studies, additional orthogonal biophysical techniques (e.g., filter-binding, SPR, or BLI) will be employed to further validate and refine the protein–aptamer interaction models.’</p>
<p>(3) Evidence of specific binding in our assays. We emphasize that the binding observed in our EMSA experiments reflects genuine aptamer–protein interactions. As shown in Figure 2G, a control RNA (Tc) exhibited no detectable binding to RBD, whereas Ta produced a clear binding curve, confirming that the interaction is specific rather than non-specific.</p>
<disp-quote content-type="editor-comment">
<p>(3) The binding energies estimated from calculations and those obtained from the gel-shift experiments are vastly different, as calculated from the <italic>K<sub>d</sub></italic> measurements, making them useless for comparison, except for estimating relative affinities.</p>
</disp-quote>
<p>Author Reply: We thank the reviewer for raising this important point. CAAMO was developed as a post-SELEX optimization tool with the explicit goal of predicting relative affinity changes (<italic>ΔΔG</italic>) rather than absolute binding free energies (<italic>ΔG</italic>). Empirically, CAAMO correctly predicted the direction of affinity change for 5 out of 6 designed variants (e.g., <italic>ΔΔG</italic> &lt; 0 indicates enhanced binding free energy relative to WT); such predictive power for relative ranking is highly valuable for prioritizing candidates for experimental testing. Our prior work on RNA–protein interactions likewise supports the reliability of relative affinity predictions (see: Nat Commun 2023, doi:10.1038/s41467-023-39410-8). The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 24 in the revised manuscript)</p>
<p>‘While EMSA provides semi-quantitative affinity estimates, the close agreement between experimental EMSA trends and FEP-calculated ΔΔG values supports the robustness of the relative affinity changes reported here.’</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the Authors:</bold></p>
<p><bold>Reviewer #1 (Recommendations for the authors)</bold></p>
<p>(1) Overall, the paper is well-written and, in the opinion of this reviewer, could remain as it is.</p>
</disp-quote>
<p>We thank the reviewer for the positive evaluation and supportive comments regarding our manuscript. We are grateful for the endorsement of its quality and suitability for publication.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors)</bold></p>
<p>(1) All molecules present in experiments need to be reported with their final concentrations (not µg).</p>
</disp-quote>
<p>We thank the reviewer for raising this important point. In the revised manuscript, all antibody amounts previously reported in µg have been converted to their corresponding molar concentrations in Fig. 1F and Fig. 5D. In addition, the exact antibody concentrations used in the EMSA assays are now explicitly stated in the Materials and Methods section under “EMSA experiments.” The following has been added to “EMSA experiments” of the revised manuscript. (Page 30 in the revised manuscript)</p>
<p>‘For competitive binding experiments, 40 μM of RBP proteins, 5 μM of annealed Cy3-labelled RNAs and increasing concentrations of SARS-CoV-2 neutralizing antibody 40592-R001 (0–1.67 μM) were mixed in the EMSA buffer and incubated at room temperature for 20 min.’</p>
<disp-quote content-type="editor-comment">
<p>(2) An independent <italic>K<sub>d</sub></italic> measurement, for example, using a filter binding assay, would greatly strengthen the results.</p>
</disp-quote>
<p>We thank the reviewer for this constructive suggestion and agree that an orthogonal biophysical measurement (e.g., a filter-binding assay, SPR or BLI) would further strengthen confidence in the reported dissociation constants. Unfortunately, all available SARS-CoV-2 RBD protein used in this study has been fully consumed and, due to current supply limitations, we were unable to perform new orthogonal binding experiments for the revised manuscript. We regret this limitation and have documented it in the Discussion as an item for future work.</p>
<p>Importantly, although we could not perform a new filter-binding experiment at this stage, we have multiple independent lines of evidence that support the reliability of the EMSA-derived affinity trends reported in the manuscript:</p>
<p>(1) Rigorous EMSA design and reproducibility. All EMSA binding curves reported in the manuscript (e.g., Figs. 2F–G, 4E–F, 5A and Fig. S9) are derived from three independent biological replicates and include standard deviations; the measured binding curves show good reproducibility across replicates.</p>
<p>(2) Appropriate positive and negative controls. Our gel assays include clear internal controls. The literature-reported strong binder Ta forms a distinct aptamer–RBD complex band under our conditions, whereas the negative-control aptamer Tc shows no detectable binding under identical conditions (see Fig. 2F). These controls demonstrate that the EMSA system discriminates specific from non-binding sequences with high sensitivity.</p>
<p>(3) Orthogonal computational validation (FEP) that agrees with experiment. The central strength of the CAAMO framework is the integration of rigorous physics-based calculations with experiments. We performed FEP calculations for the selected single-nucleotide mutations and computed <italic>ΔΔG</italic> values for each mutant. The direction and rank order of binding changes predicted by FEP are in good agreement with the EMSA measurements: five of six FEP-predicted improved mutants (Ta<sup>G34C</sup>, Ta<sup>G34U</sup>, Ta<sup>G34A</sup>, Ta<sup>C23A</sup>, Ta<sup>C23U</sup>) were experimentally confirmed to have stronger apparent affinity than wild-type Ta (see Fig. 4D–F, Table S2), yielding a success rate of 83%. The concordance between an independent, rigorous computational method and our experimental measurements provides strong mutual validation.</p>
<p>(4) Independent competitive binding experiments. We additionally performed competitive EMSA assays against a commercial neutralizing monoclonal antibody (40592-R001). These competition experiments show that Ta<sup>G34C</sup>–RBD complexes are resistant to antibody displacement under conditions that partially displace the wild-type Ta–RBD complex (see Fig. 5D). This result provides an independent, functionally relevant line of evidence that Ta<sup>G34C</sup> binds RBD with substantially higher affinity and specificity than WT Ta under our assay conditions.</p>
<p>Given these multiple, independent lines of validation (rigorous EMSA replicates and controls, FEP agreement, and antibody competition assays), we are confident that the relative affinity improvements reported in the manuscript are robust, even though the absolute <italic>K<sub>d</sub></italic> values measured by EMSA are not directly comparable to surface-based methods (EMSA typically reports larger apparent <italic>K<sub>d</sub></italic> values than SPR/BLI due to methodological differences). The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 24 in the revised manuscript)</p>
<p>‘Although the absolute <italic>K<sub>d</sub></italic> values determined by EMSA cannot be directly compared with surface-based methods such as SPR or BLI, the relative affinity trends remain highly consistent. While EMSA provides semi-quantitative affinity estimates, the close agreement between experimental EMSA trends and FEP-calculated ΔΔG values supports the robustness of the relative affinity changes reported here. In future studies, additional orthogonal biophysical techniques (e.g., filter-binding, SPR, or BLI) will be employed to further validate and refine the protein–aptamer interaction models.’</p>
<disp-quote content-type="editor-comment">
<p>(3) The project would really benefit from a different aptamer-target system. Starting with a 100 µM aptamer is really not adequate.</p>
</disp-quote>
<p>We thank the reviewer for this important suggestion and for highlighting the value of testing the CAAMO framework in additional aptamer–target systems.</p>
<p>First, we wish to clarify the rationale for selecting the Ta–RBD system as the proof-of-concept. The Ta aptamer is not an arbitrary or weak binder: it was originally identified by independent SELEX experiments and subsequently validated by rigorous biophysical assays (SPR and BLI) (see: Proc. Natl. Acad. Sci. 2021, doi: 10.1073/pnas.2112942118). That study confirmed that Ta exhibits high-affinity and high-specificity binding to the SARS-CoV-2 RBD, which is why it serves as a well-characterized and biologically relevant system for method validation and optimization. We have added a brief clarification to the “Introduction” to emphasize these points. The following has been added to “Introduction” of the revised manuscript. (Page 4 in the revised manuscript)</p>
<p>‘This aptamer was originally identified through SELEX and subsequently validated using surface plasmon resonance (SPR) and biolayer interferometry (BLI), which confirmed its high affinity and high specificity toward the RBD. Therefore, Ta provides a well-characterized and biologically relevant starting point for structure-based optimization.’</p>
<p>Second, we agree that apparent discrepancies in absolute <italic>K<sub>d</sub></italic> values can arise from different experimental platforms. Surface-based methods (SPR/BLI) and gel-shift assays (EMSA) have distinct measurement principles; EMSA yields semi-quantitative, solution-phase, apparent <italic>K<sub>d</sub></italic> values that are not directly comparable in absolute magnitude to surface-based measurements. Crucially, however, our study focuses on relative affinity change. EMSA is well suited for parallel, comparative measurements across multiple variants when all samples are assayed under identical conditions, and thus provides a reliable readout for ranking and validating designed mutations. We have added a short statement in the “Discussion and conclusion”. The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 24 in the revised manuscript)</p>
<p>‘Although the absolute <italic>K<sub>d</sub></italic> values determined by EMSA cannot be directly compared with surface-based methods such as SPR or BLI, the relative affinity trends remain highly consistent. While EMSA provides semi-quantitative affinity estimates, the close agreement between experimental EMSA trends and FEP-calculated ΔΔG values supports the robustness of the relative affinity changes reported here. In future studies, additional orthogonal biophysical techniques (e.g., filter-binding, SPR, or BLI) will be employed to further validate and refine the protein–aptamer interaction models.’</p>
<p>Third, and importantly, CAAMO is inherently generalizable. In addition to the Ta–RBD application presented here, we have already begun applying CAAMO to other aptamer–target systems. In particular, we have successfully deployed the framework in preliminary optimization studies of RNA aptamers targeting the epidermal growth factor receptor (EGFR) (see: Gastroenterology 2021, doi: 10.1053/j.gastro.2021.05.055) (see Author response image 2). These preliminary results support the transferability of the CAAMO pipeline beyond the SARS-CoV-2 RBD system. We have added a short statement in the “Discussion and conclusion”. The following has been added to “Discussion and conclusion” of the revised manuscript. (Page 259 in the revised manuscript)</p>
<p>‘In addition to the Ta–RBD system, the CAAMO framework itself is inherently generalizable. More work is currently underway to apply CAAMO to optimize aptamers targeting other therapeutically relevant proteins, such as the epidermal growth factor receptor (EGFR) [45], in order to further explore its potential for broader aptamer engineering.’</p>
<fig id="sa2fig4">
<label>Author response image 2.</label>
<caption>
<title>Overview of the predicted binding model of the EGFR–aptamer complex generated using the CAAMO framework.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-107785-sa2-fig4.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>(4) Several RBD variants should be tested, as well as other proteins, for specificity. At such weak affinities, it is likely that these are non-specific binders.</p>
</disp-quote>
<p>We thank the reviewer for this important concern. Below we clarify the basis for selecting Ta and its engineered variants, summarize the experimental controls that address specificity, and present the extensive <italic>in silico</italic> variant analysis we performed to assess sensitivity and breadth of binding.</p>
<p>(1) Origin and validation of Ta. As noted in our response to “Comment (3)”, the Ta aptamer was not chosen arbitrarily. Ta was identified by independent SELEX with both positive and negative selection and subsequently validated using surface-based biophysical assays (SPR and BLI), which reported low-nanomolar affinity and high specificity for the SARS-CoV-2 RBD. Thus, Ta is a well-characterized, experimentally validated starting lead for method development and optimization.</p>
<p>(2) Experimental specificity controls. We appreciate the concern that weak apparent affinities can reflect non-specific binding. As noted in our response to “Comment (2)”, we applied multiple experimental controls that argue against non-specificity: (i) a literature-reported weak binder (Tc) was used as a negative control and produced no detectable complex under identical EMSA conditions (see Figs. 2F–G), demonstrating the assay’s ability to discriminate non-binders from specific binders; (ii) competitive EMSA assays with a commercial neutralizing monoclonal antibody (40592-R001) show that both Ta and Ta<sup>G34C</sup> engage the same or overlapping RBD site as the antibody, and that Ta<sup>G34C</sup> is substantially more resistant to antibody displacement than WT Ta (see Figs. 3D–E, 5D). Together, these wet-lab controls support that the observed aptamer-RBD bands reflect specific interactions rather than general, non-specific adsorption.</p>
<p>(3) Variant and specificity analysis by rigorous FEP calculations. To address the reviewer’s request to evaluate variant sensitivity, we performed extensive free energy perturbation combined with Hamiltonian replica-exchange molecular dynamics (FEP/HREX) for improved convergence efficiency and increased simulation time to estimate relative binding free energy changes (<italic>ΔΔG</italic>) of both WT Ta and the optimized Ta<sup>G34C</sup> against a panel of RBD variants. Results are provided in Tables S4 and S5. Representative findings include: For WT Ta versus early lineages, FEP reproduces the experimentally observed trends: Alpha (B.1.1.7; N501Y) yields <italic>ΔΔG<sub>FEP</sub></italic> = −0.42 ± 0.07 kcal/mol (<italic>ΔΔG<sub>exp</sub></italic> = −0.24), while Beta (B.1.351; K417N/E484K/N501Y) gives <italic>ΔΔG<sub>FEP</sub></italic> = 0.64 ± 0.25 kcal/mol (<italic>ΔΔG<sub>exp</sub></italic> = 0.36) (see Table S4). The agreement between the computational and experimental results supports the fidelity of our computational model for variant assessment. For the engineered Ta<sup>G34C</sup>, calculations across a broad panel of variants indicate that Ta<sup>G34C</sup> retains or improves binding (<italic>ΔΔG</italic> &lt; 0) for the majority of tested variants, including Alpha, Beta, Gamma and many Omicron sublineages. Notable examples: BA.1 (<italic>ΔΔG</italic> = −3.00 ± 0.52 kcal/mol), BA.2 (<italic>ΔΔG</italic> = −2.54 ± 0.60 kcal/mol), BA.2.75 (<italic>ΔΔG</italic> = −5.03 ± 0.81 kcal/mol), XBB (<italic>ΔΔG</italic> = −3.13 ± 0.73 kcal/mol) and XBB.1.5 (<italic>ΔΔG</italic> = −2.28 ± 0.96 kcal/mol). A minority of other Omicron sublineages (e.g., BA.4 and BA.5) show modest positive <italic>ΔΔG</italic> values (2.11 ± 0.67 and 2.27 ± 0.68 kcal/mol, respectively), indicating a predicted reduction in affinity for those specific backgrounds. Overall, these data indicate that the designed Ta<sup>G34C</sup> aptamer can maintain its binding ability with most SARS-CoV-2 variants, showing potential for broad-spectrum antiviral activity (see Table S5). The following has been added to “Results” of the revised manuscript. (Page 22 in the revised manuscript)</p>
<p>‘2.6 Binding performance of Ta and Ta<sup>G34C</sup> against SARS-CoV-2 RBD variants</p>
<p>To further evaluate the binding performance and specificity of the designed aptamer Ta<sup>G34C</sup> toward various SARS-CoV-2 variants [39], we conducted extensive free energy perturbation combined with Hamiltonian replica-exchange molecular dynamics (FEP/HREX) [40–42] for both the wild-type aptamer Ta and the optimized Ta<sup>G34C</sup> against a series of RBD mutants. The representative variants include the early Alpha (B.1.1.7) and Beta (B.1.351) lineages, as well as a panel of Omicron sublineages (BA.1–BA.5, BA.2.75, BQ.1, XBB, XBB.1.5, EG.5.1, HK.3, JN.1, and KP.3) carrying multiple mutations within the RBD region (residues 333–527). For each variant, mutations within 5 Å of the bound aptamer were included in the FEP to accurately estimate the relative binding free energy change (<italic>ΔΔG</italic>).</p>
<p>For the wild-type Ta aptamer, the FEP-predicted binding affinities toward the Alpha and Beta RBD variants were consistent with the previous experimental results, further validating the reliability of our model (see Table S4). Specifically, Ta maintained comparable or slightly enhanced binding to the Alpha variant and showed only marginally reduced affinity for the Beta variant.</p>
<p>In contrast, the optimized aptamer Ta<sup>G34C</sup> exhibited markedly improved and broad-spectrum binding capability toward most tested variants (see Table S5). For early variants such as Alpha, Beta, and Gamma, Ta<sup>G34C</sup> maintained enhanced affinities (<italic>ΔΔG</italic> &lt; 0). Notably, for multiple Omicron sublineages—including BA.1, BA.2, BA.2.12.1, BA.2.75, XBB, XBB.1.5, XBB.1.16, XBB.1.9, XBB.2.3, EG.5.1, XBB.1.5.70, HK.3, BA.2.86, JN.1 and JN.1.11.1—the calculated binding free energy changes ranged from −1.89 to −7.58 kcal/mol relative to the wild-type RBD, indicating substantially stronger interactions despite the accumulation of multiple mutations at the aptamer–RBD interface. Only in a few other Omicron sublineages, such as BA.4, BA.5, and KP.3, a slight reduction in binding affinity was observed (<italic>ΔΔG</italic> &gt; 0).</p>
<p>These computational findings demonstrate that the Ta<sup>G34C</sup> aptamer not only preserves high affinity for the RBD but also exhibits improved tolerance to the extensive mutational landscape of SARS-CoV-2. Collectively, our results suggest that Ta<sup>G34C</sup> holds promise as a high-affinity and potentially cross-variant aptamer candidate for targeting diverse SARS-CoV-2 spike protein variants, showing potential for broad-spectrum antiviral activity.’</p>
<p>The following has been added to “Materials and Methods” of the revised manuscript. (Page 29 in the revised manuscript)</p>
<p>‘4.7 FEP/HREX</p>
<p>To evaluate the binding sensitivity of the optimized aptamer Ta<sup>G34C</sup> toward SARS-CoV-2 RBD variants, we employed free energy perturbation combined with Hamiltonian replica-exchange molecular dynamics (FEP/HREX) simulations for enhanced sampling efficiency and improved convergence. The relative binding free energy changes (<italic>ΔΔG</italic>) upon RBD mutations were estimated as:</p>
<p><italic>ΔΔ𝐺 = Δ𝐺<sub>bound</sub> − Δ𝐺<sub>free</sub></italic></p>
<p>where <italic>ΔG<sub>bound</sub></italic> and <italic>ΔG<sub>free</sub></italic> represent the RBD mutations-induced free energy changes in the complexed and unbound states, respectively. All simulations were performed using GROMACS 2021.5 with the Amber ff14SB force field. For each mutation, dual-topology structures were generated in a pmx-like manner, and 32 λ-windows (0.0, 0.01, 0.02, 0.03, 0.06, 0.09, 0.12, 0.16, 0.20, 0.24, 0.28, 0.32, 0.36, 0.40, 0.44, 0.48, 0.52, 0.56, 0.60, 0.64, 0.68, 0.72, 0.76, 0.80, 0.84, 0.88, 0.91, 0.94, 0.97, 0.98, 0.99, 1.0) were distributed uniformly between 0.0 and 1.0. To ensure sufficient sampling, each window was simulated for 5 ns, with five independent replicas initiated from distinct velocity seeds. Replica exchange between adjacent λ states was attempted every 1 ps to enhance phase-space overlap and sampling convergence. The van der Waals and electrostatic transformations were performed simultaneously, employing a soft-core potential (α = 0.3) to avoid singularities. For each RBD variant system, this setup resulted in an accumulated simulation time of approximately 1600 ns (5 ns × 32 windows × 5 replicas × 2 states). The Gromacs bar analysis tool was used to estimate the binding free energy changes.’</p>
<p>Tables S4 and S5 have been added to Supplementary Information of the revised manuscript.</p>
</body>
</sub-article>
</article>